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Abstract: The purpose of this study is to examine whether genetic variation in CYP1A2 (-
163A>C, rs762551) influences the effects of acute caffeine supplementation on 
neuromuscular function of the lower body at rest and in response to a fatiguing work 
bout. Forty-two young, healthy males completed the entire study protocol and were 
genotyped for CYP1A2 enzyme. Subjects were then classified as AA (FAST: n = 26) or 
AC/CC (SLOW; n =16). This study consisted of 3 separate visits to the laboratory, a 
familiarization session and 2 experimental sessions: caffeine (CAF; 6 mg/kg/bw) or 
placebo (PLA). During each session, neuromuscular function, including motor unit 
behavior, muscle activation, spinal and supraspinal excitability, and muscle contractile 
properties were assessed. Additionally, each experimental visit ended with repeated, 
intermittent submaximal contractions at 50% of the subject’s maximum effort to fatigue. 
The main findings from this investigation were the overall lack of ergogenic effects of 
caffeine on neuromuscular function of the lower body musculature. Specifically, no 
significant alterations in motor unit behavior, muscle activation, or spinal or supraspinal 
excitability were found from pre- to post-testing in either condition. However, the present 
data suggest that caffeine may augment the decline seen in muscle contractile properties 
in the placebo condition. The present data also suggests a limited role, if any, for the 
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Caffeine (1,3,7-trimethylxanthine) is the most widely consumed, central nervous 
system stimulant in the world. Its primary mechanism of action is thought to be as an 
adenosine receptor antagonist, preventing the decline in wakefulness seen throughout the 
day. Caffeine can also affect muscle activation, potentially through peripheral, spinal, 
and/or supraspinal pathways (Fimland et al. 2010; Kalmar 2005) , as adenosine receptors 
are located throughout a variety of tissues (Reppert et al. 1991). At the spinal level, 
caffeine has been reported to increase motor neuron excitability (Kalmar et al. 2006; 
Walton et al. 2003)  and increase the self-sustained firing rate of motor units (Walton et 
al. 2002). Additionally, another potential mechanism is a change in calcium handling and 
kinetics following caffeine supplementation, which has been supported previous work 
showing an increase in muscular twitch force and twitch time (Bazzucchi et al. 2011; 
Lopes et al. 1983). Despite the lack of clear mechanism (Allen et al. 2008; Penner et al. 
1989) and caffeine’s widespread use as an ergogenic aid, its effects on muscle function, 
and specifically muscle strength, have been relatively mixed. For example, a meta-
analysis by Warren et al. (2010) showed a modest effect for caffeine on maximal 
voluntary contraction strength (effect size = 0.19). However, other studies have
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reported no change (Behrens et al. 2015b; Fimland et al. 2010) or even a decrease (Bond et 
al. 1986) in muscular function following caffeine supplementation. Interestingly, these 
effects may be muscle specific (Mau-Moeller et al. 2013), as the majority of positive changes 
in strength have been seen in the quadriceps femoris, with largely equivocal effects observed 
in the triceps surae musculature.  
In terms of maximal strength, Bazzucchi et al. (2011) saw a significant increase in 
MVIC of the biceps brachii an hour after caffeine supplementation, with no change seen 
following placebo ingestion, as did Behrens et al. (2015a) in the quadriceps. These results are 
supported by numerous other investigations (Behrens et al. 2015a; Goldstein et al. 2010; 
Jacobson et al. 1992; Kalmar and Cafarelli 2006; Kalmar and Cafarelli 1999; Kalmar et al. 
2006; Park et al. 2008). However, several other investigations suggest that caffeine has 
minimal to no effect on MVIC. For example, Fimland et al. (2010) and many others 
(Astorino et al. 2008; Behrens et al. 2015b; Bond et al. 1986; Jacobson and Edwards 1991; 
Tarnopolsky et al. 1989; van Duinen et al. 2005) have reported no change in MVIC strength 
following caffeine ingestion. Interestingly, however, Behrens et al. (2015b) did report a 
significant improvement normalized electromyography (EMG) and  rate of torque 
development (RTD), which led the authors to suggest that caffeine may have altered the 
excitability of the spinal -motor neurons at the onset of contraction. Another potential 
explanation could be that caffeine increased corticospinal excitability during the initial phase 
of contraction and in turn, enhanced muscle activity of the triceps surae at the 0-100 and 0-
200 time intervals, which is indirectly supported previously by Kalmar and Cafarelli (1999), 
who reported an increase in voluntary activation with no change in h-reflex, suggesting 
corticospinal mechanisms. Further support for this hypothesis is found in the work of 
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Behrens et al. (2015a), who reported a significant increase in MVC strength during eccentric, 
concentric and isometric muscle actions following caffeine administration, which the authors 
concluded was due to an increase in voluntary activation. The authors also saw an increase in 
RTD (0-200), which the authors attributed to increased neural drive. Based on the above 
described studies, Behrens et al. (2015a) suggested that caffeine is most likely exerting its 
effect centrally, as opposed to influencing in excitability of spinal -motor neurons.  
It has been shown that central adenosine a2a receptor agonists depress the firing of 
cerebral cortical neurons and lead to hypoactivity, depression of locomotor activity and 
impairment of coordination (Phillis et al. 1979). Thus, caffeine may improve force 
production via antagonism of the adenosine a2a receptors. In support of this hypothesis, 
Bazzucchi et al. (2011) observed an increase in biceps brachii EMG amplitude following 
caffeine administration, which the authors attributed to greater recruitment high-threshold 
MUs, as previously proposed by Kalmar and Cafarelli (1999). Behrens (Behrens et al. 2015a; 
Behrens et al. 2015b) reported increased neural drive following caffeine supplementation, 
which was evidenced by increase EMG amplitude during the onset of torque production. 
Moreover, Bazzucchi et al. (2011) observed increases in torque across the torque-velocity 
relationship, supporting their hypothesis of increased capacity to recruit higher-threshold 
MUs with caffeine supplementation. However, they did not observe a change in EMG 
amplitude during non-explosive contractions. Thus, this may support the conclusions of 
Warren et al. (2010), who reported that the most likely mechanism for the modest 
improvement in MVC reported from their review was due to increased voluntary activation. 
In contrast, however, Fimland et al. (2010) reported no changes in EMG amplitude following 
caffeine. This is supported by the work of Greer and colleagues (2006), who found no change 
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in Wingate performance or EMG parameters (mean power frequency, integrated EMG 
amplitude, etc.) following caffeine supplementation (5 mg/kg), when compared to placebo. 
However, it is also interesting to point out the potential muscle and/or contraction specific 
effects of caffeine. For example, the contribution of cortical and spinal centers differ based 
on contraction type and may be partly responsible for the differences observed (Duchateau 
and Baudry 2013). This is supported by previous work, where H-reflexes and motor evoked 
potentials were smaller during eccentric contractions, when compared to isometric or 
concentric contractions (Duclay and Martin 2005; Gruber et al. 2009). Additionally, the 
review by Warren et al. (2010) showed the largest effect of caffeine on voluntary activation 
in the quadriceps femoris (ES = 0.67), which is likely because voluntary activation is often 
lower for the knee extensors than for other lower body musculature or muscle groups in the 
upper extremity (Mau-Moeller et al. 2013).  
While the literature on the effects of caffeine on neuromuscular function are largely 
equivocal, the H-Reflex and V-Wave (volitional wave) responses to caffeine are quite 
uniform. H-reflex and V-wave can be used to analyze modulations at the spinal level 
(Aagaard et al. 2002; Zehr 2002). H-reflex reflects the activation of the -motor neurons by 
the I afferent pathways (Schieppati 1987), whereas the V-wave reflects the descending 
neural drive from the -motor neuron to the muscle (Aagaard et al. 2002; Schieppati 1987; 
Seynnes et al. 2010). While Walton and colleagues (2003)found an increase in normalized h-
reflex following caffeine administration, the vast majority of investigations consistently 
report no change in H-reflex at rest (Behrens et al. 2015a; Behrens et al. 2015b; Kalmar and 
Cafarelli 1999) or during weak contractions (Behrens et al. 2015a; Kalmar and Cafarelli 
1999), although these authors have suggested that the lack of change in the soleus may be 
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due to a relatively high activation at rest (Del Balso and Cafarelli 2007; Racinais et al. 2008). 
Similarly, an unchanged V-wave (Fimland et al. 2010) response prior to and following 
caffeine-administration has also been reported. It is worth noting that the H-reflex and V-
wave are influenced by presynaptic inhibition, reciprocal inhibition, and recurrent inhibition 
(Crone and Nielsen 1994; Hultborn and Pierrot‐Deseilligny 1979; Zehr 2002). Therefore, 
neural drive could have increased but inhibitory factors could have increased as well. 
However, the lack of change in EMG amplitude and/or the modulation of evoked spinal 
reflex responses because of alterations in presynaptic inhibition seem unlikely.  
Finally, peripheral mechanisms cannot be excluded as potential explanations for 
caffeine’s effects, although most of the evidence points towards a CNS-related mechanism. 
In vitro evidence has suggested that caffeine increases intracellular calcium release from the 
sarcoplasmic reticulum (Allen et al. 2008), potentially due to the interaction of caffeine and 
the ryanodine receptors of the sarcoplasmic reticulum (Penner et al. 1989). Caffeine could 
also increase performance due to increased calcium mobilization and increased sensitivity of 
myofibrils to calcium (Nehlig and Debry 1994), and/or slower reuptake of calcium to the 
sarcoplasmic reticulum, leading to greater intracellular calcium availability (Allen et al. 
2008). Bazzucchi et al. (2011)found significant changes myoelectric and mechanical 
responses of the biceps brachii, which they attributed to increases in muscle contractility and 
conduction velocity following caffeine supplementation. As conduction velocity could 
potentially reflect changes in MU recruitment strategies, changes in contractile properties, 
and/or excitability of the sarcolemma (Andreassen and Arendt-Nielsen 1987; Solomonow et 
al. 1989), although the authors hypothesized that sarcolemmic excitability was the most 
likely to be influenced by caffeine.  
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As mentioned previously, much of the data suggest that caffeine’s effects on 
neuromuscular function occurs via changes in the CNS, specifically as an increase in 
voluntary activation following caffeine supplementation (Behrens et al. 2015a; Meyers and 
Cafarelli 2005; Plaskett and Cafarelli 2001; Tarnopolsky and Cupido 2000). It has been 
suggested that the central activation ratio (CAR) and interpolated twitch technique (ITT) are 
not appropriate to distinguish between supraspinal and spinal activation (Behrens et al. 
2015b). However, the overall lack of change in the H-reflex, along with the general increase 
in voluntary activation, points towards modulation at the supraspinal level (Kalmar and 
Cafarelli 1999). This is supported by later work from Kalmar and coworkers (2006), who 
found that motor-evoked potentials and cortically evoked twitches of the VL during weak 
isometric contractions were increased following caffeine ingestion, which confirmed the 
hypothesis of Phillis et al. (1979). This hypothesis is also potentially supported by the 
antagonist effects of methylxanthines on adenosine and the adenine nucleotides enhanced 
spontaneous firing rates of cerebral cortical neurons (Phillis et al. 1979). 
Similar to the data describing the influence of caffeine on force production, 
conflicting evidence on the influence of caffeine on the manifestation of fatigue exists. For 
example, Fimland et al. (2010) saw no difference between placebo and caffeine in 
physiological parameters (MVIC, M-Wave, V-wave, EMG amplitude) immediately 
following and during recovery from a fatiguing protocol. Caffeine also did not improve time 
to fatigue (Fimland et al. 2010). However, Meyers and Cafarelli (2005) found a significant 
increase in time to fatigue during submaximal isometric contractions to fatigue, despite no 
changes in whole muscle activation. They found that the amplitude of evoked twitches and 
the instantaneous relaxation rate were significantly correlated in both the placebo and 
7 
 
caffeine conditions, indicating that the increase in time to exhaustion may have been due to 
caffeine’s effect on calcium reuptake and subsequent twitch force (Meyers and Cafarelli 
2005). In support of this, previous work by Kalmar and Cafarelli (1999) saw a 25.8% 
increase in time to fatigue during sustained MVC’s following caffeine. The authors attributed 
the increased neural drive with caffeine and thus, slight increases in strength, with the 
increased time to fatigue (Kalmar and Cafarelli 1999; Plaskett and Cafarelli 2001). Meyers 
and Cafarelli (2005) demonstrated significant increase in time to exhaustion in “responders” 
following caffeine, but not in “non-responders”, suggesting that the responses to caffeine are 
probably subject dependent (Kalmar 2005). Interestingly, the dosage in most of these 
investigations was similar (i.e. 5-8 mg/kg/bw) and thus is probably not due to insufficient 
caffeine dosage. As mentioned previously, it has been hypothesized that these differences 
may be due to muscle tested and/or individual differences in the subject’s caffeine 
metabolism.  
Recently, the literature has hypothesized a potential role of genetic polymorphisms in 
caffeine metabolism, providing a genetic link to the “responder/non-responder” classification 
laid out previously by Meyers and Cafarelli (2005). Since 95% of caffeine is metabolized by 
a single nucleotide polymorphism (SNP) at intron 1 of the cyctochrome P450 enzyme 
(CYP1A2), several investigations have examined the effects of the CYP1A2 genotype on 
caffeine metabolism and subsequent exercise performance (Algrain et al. 2016; Giersch et al. 
2018; Guest et al. 2018; Puente et al. 2018; Salinero et al. 2017; Womack et al. 2012). 
Interestingly, those who have an A allele in position 734 of the CYP1A2 genotype have 
increased enzyme activity and experience faster caffeine metabolism when compared to 
those with a C allele in the same position (Han et al. 2001; Sachse et al. 1999). Therefore, 
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those with a homozygous A allele are considered ‘fast-metabolizers’, with those with the 
AC/CC alleles are considered ‘slow metabolizers’. This provides a potentially interesting 
physiological rationale for the divergent responses reported in a large portion of the caffeine 
literature and on an individual subject level (Pickering and Kiely 2018). Further, there is 
evidence to suggest that those who possess the slow genotypes may be at a greater risk for 
cardiovascular related events following caffeine administration (Cornelis et al. 2006; Sachse 
et al. 2003; Sachse et al. 1999), providing a potentially useful clinical utility to CYP1A2 
genotyping.   
1.2 Study Purpose  
The purpose of this study is to examine whether genetic variation in CYP1A2 (-
163A>C, rs762551) influences the effects of acute caffeine supplementation on 
neuromuscular function of the lower body at rest and in response to a fatiguing work bout.  
1.3 Research Questions & Hypotheses 
1.3.1 Does acute caffeine supplementation improve neuromuscular function?  
HO1.3.1: There will be no difference in neuromuscular function following either caffeine or 
placebo.  
HA1.3.1: Acute caffeine supplementation will significantly improve neuromuscular function 
when compared to placebo.  
1.3.2 Does CYP1A2 genotype influence the changes in neuromuscular function following 
acute caffeine supplementation?  
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HO1.3.2: There will be no difference in neuromuscular function following acute caffeine 
supplementation between CYP1A2 genotypes.  
HA1.3.2: Those with the homozygous A (AA) CYP1A2 genotype will exhibit more 
pronounced improvements in neuromuscular function than those with a C CYP1A2 genotype 
following acute caffeine administration.  
1.3.3 Does acute caffeine supplementation influence the fatigability of the knee extensors? 
HO1.3.3: There will be no differences in the fatigability of knee extensors between the caffeine 
and placebo conditions.  
HA1.3.3: Caffeine will delay the onset of fatigue in the knee extensors, when compared to 
placebo.  
1.3.4 Does CYP1A2 genotype influence the changes in fatigability following acute caffeine 
supplementation?  
HO1.3.4: There will be no difference in fatigability following acute caffeine supplementation 
between CYP1A2 genotypes.  
HA1.3.4: Those with the homozygous A (AA) CYP1A2 genotype will exhibit a more 
pronounced delay in fatigue of the knee extensors than those with a C CYP1A2 genotype 
following acute caffeine administration.  
1.4 Significance of Study  
The present investigation has the potential to elucidate the divergent neuromuscular 
responses to caffeine widely reported in the literature to date. Additionally, the findings of 
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this investigation have the potential to help create more accurate and robust caffeine 
recommendations for improved exercise performance.  
1.5 Delimitations 
1. Approximately 42 young, healthy males participated in this investigation.  
2. Only participants between the ages of 18 and 35 years of age were be recruited for this 
investigation.  
3. All participants were healthy and free from any neuromuscular or musculoskeletal 
conditions at the time of participation.  
4. The participants performed both voluntary and involuntary (i.e. evoked) contractions. 
5. Data was only be collected from the musculature of the right leg.  
6. All data was collected in the seated position.  
7. All muscular contractions collected in this investigation were isometric.   
8. Only active males were recruited to participate in this investigation. Thus, activity levels 
and exercise status may vary within the sample.  
1.6 Limitations  
1. The recruitment process will not be truly randomized, as participants were recruited by 
word of mouth.  
2. The data presented from this investigation are from a rather homogenous sample, thus, the 
applicability to other populations may be limited.  
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3. As the study design involves a number of maximal contractions and a submaximal fatigue 
protocol, differences in motivation levels between subjects may influence results. 
1.7 Assumptions 
1. All participants abstained from caffeine during the duration of the investigation.  
2. All participants provided accurate information on their health and exercise status.  
3. All equipment used in the investigation was calibrated and functioning.  







REVIEW OF LITERATURE 
The following literature review will include previous research studies that are 
relevant to the purpose of this study. Each study will be summarized and the results of the 
study will be provided along with the interpretations of the authors. The aim of this 
review of the literature is to focus on the neuromuscular responses to caffeine and the 
influence of the CYP1A2 genotype, and the potential changes in the variables assessed in 
the methods section.  
2.1 CYP1A2 Genotype & Caffeine  
Algrain et al. (2016)  
The purpose of this study was to determine if a polymorphism in the cytochrome 
P450 CYP1A2 gene impacts performance following caffeine supplementation in 
recreational cyclists. Following either caffeine or placebo chewing gum, serum blood 
samples were taken at baseline, during the warm-up and immediately before and after the 
trial. The authors found no improvement in performance between conditions, as well as 
no effect for genotype, defined as AA allele carriers or C carriers. CYP1A2 genotype did 
not influence the ergogenic effects of caffeine, nor the circulating caffeine concentrations 
of caffeine.  
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Cornelis et al. (2006) 
The purpose of this investigation was to determine whether the CYP1A2 
genotype modifies the association between coffee consumption and the risk of acute 
nonfatal myocardial infarction. The authors found that fifty-one percent of those that had 
a nonfatal myocardial infarction and fifty-four percent of controls (i.e. no myocardial 
infarction) were carriers of the slow allele (*1F). The authors reported that there was an 
increased risk of myocardial infarction with increased coffee consumption, but only in 
those who were carriers of the *1F allele. 
Giersch et al. (2018) 
The purpose of this investigation was to determine whether CYP1A2 
polymorphism affects caffeine metabolism and subsequent exercise performance between 
the difference genotypes. Sixty minutes following the ingestion of either 6 mg/kg of 
bodyweight or placebo (all-purpose flour), subjects completed a 3 km cycling time trial. 
Subjects were then divided into slow (AC heterozygous or CC homozygous) or fast (AA 
homozygous) metabolizers. Slow metabolizers exhibited significantly higher serum 
caffeine 1-hour post-ingestion. However, no significant differences in measured caffeine 
metabolite, metabolite: caffeine ratio or paraxanthine:caffeine ratio was seen. Caffeine 
resulted in a significant decrease in time trial performance (7.1 ± 13.9 s.), with no 
significant differences between groups. Thus, genotype variation appears to effect serum 





de Souza Gonçalves et al. (2017) 
The purpose of this study was to investigate of habitual caffeine intake on aerobic 
exercise performance responses to acute caffeine supplementation. Participants were 
allocated into 3 groups based on habitual caffeine intake: low (58 ± 29 mg·d-1), moderate 
(143 ± 25 mg·d-1), and high consumers (351 ± 139 mg·d-1). Participants then completed 3 
cycling time trials following the ingestion: caffeine (6 mg/kg of bodyweight), placebo, 
and no supplement. Results showed that caffeine significantly improved time trial 
performance, when compared to both placebo and no supplement conditions. 
Furthermore, the results showed no effect of habitual caffeine intake on exercise 
performance. The authors suggested that benefits of caffeine on time trial performance 
are not influenced by habitual caffeine intake.  
Guest et al. (2018) 
The purpose of this study was to determine whether CYP1A2 gene variation 
modifies the ergogenic effects of caffeine in a 10-km cycling time trial. Subjects 
completed 3 10-km time trials under the following conditions: 0, 2, or 4 mg/kg of 
bodyweight of caffeine. Results showed a 3% decrease in performance following 4 
mg/kg of caffeine. However, those with AA homozygous (i.e. fast metabolizers) 
genotype exhibited a 4.8% and 6.8% decrease in performance with 2 and 4 mg/kg of 
caffeine, respectively. Those with a CC homozygous (i.e. slow metabolizers) genotype 
exhibited a 13.7% increase when compared to placebo. No effects were seen in those 
with AC heterozygous genotypes. The authors suggested that CYP1A2 genotype plays a 
significant role in potential effects from caffeine supplementation.  
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Pataky et al. (2016)  
The purpose of this investigation was to examine the efficacy of a caffeine mouth 
rinse on cycling performance, as well as to determine whether its efficacy was influenced 
by CYP1A2 genotype. The results of this study indicate that only those with an AC 
heterozygous genotype of the CYP1A2 gene received a significant increase in 
performance following 6 mg/kg/bw of caffeine ingestion, although both AA and AC 
genotypes significantly improved performance following caffeine ingestion plus a 
caffeine mouth rinse, with no significant differences between AA and AC. Interestingly, 
the authors reported that both caffeine and caffeine plus caffeine mouth rinse elicited 
greater improvements before 10:00 am, when compared with after 10:00 am. The authors 
concluded that both genotype and time of day can influence the efficacy of caffeine to 
improve time-trial performance.  
Puente et al. (2018)  
The purpose of this investigation was to examine the influence of the CYP1A2 
gene polymorphism on the ergogenic effects of caffeine in elite basketball players. Sixty 
minutes following the ingestion of either caffeine (3 mg/kg of bodyweight) or placebo, 
subjects completed a jumping and agility tests, as well as a 20-minute simulated game. 
Subjects with the AA homozygous genotype improved jump height by 2.9 ± 3.6% 
following caffeine ingestion, while the CC homozygous group did not improve jump 
performance. Caffeine did not improve agility in either group, but improved the number 
of impacts during the simulated game in both groups. Interestingly, the AA group 
experienced self-reported insomnia following caffeine, while the CC group reported no 
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side effects. The authors thus reported a moderate beneficial effect from caffeine in those 
with the AA genotype.  
Sachse et al. (1999)  
The aim of this investigation was to determine the amount of variability of 
CYP1A2 activity is explained by a gene polymorphism in intron 1. Following the 
ingestion of 100 mg of caffeine, a population of 185 healthy and 51 smokers were 
determined as 46% homozygous for variant A, 44% were heterozygous, and 10% were 
homozygous for variant C. Significant differences between genotypes in the 5-hour 
plasma 17X/caffeine ratios were only found in those who were smoker. The authors 
found that, while no significant differences in CYP1A2 metabolic activity between 
genotypes were found between non-smokers, smokers exhibiting the homozygous A 
genotype exhibited a 1.6-fold higher metabolic activity than heterozygous or 
homozygous C genotypes. The authors concluded that the A/A genotype may be a direct 
cause of increased CYP1A2 genotype or may be genetically linked to other 
polymorphisms conferring high inducibility following caffeine administration.  
Sachse et al. (2003) 
The purpose of this investigation was to examine the influence of CYP1A2 for 
allele frequencies, linkage disequilibrium and caffeine metabolism in colorectal patients 
and healthy controls. In the most germane finding of this investigation, the authors found 
lower caffeine metabolic ratios were detected in colorectal patients than controls, but 
only in those who were smokers. The authors also found no association between 
CYP1A2 genotype and caffeine phenotype, based on the caffeine metabolite ratio.  
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Salinero et al. (2017) 
The aim of this investigation was to determine the influence of the CYP1A2 
genotype on exercise performance following a moderate dose of caffeine. Participants 
ingested either 3 mg/kg of caffeine or a placebo, following which they completed a 
Wingate test. Visual attention and side effects were also measured. Subjects were 
grouped based on CYP1A2 genotype. Acute caffeine ingestion increased peak power 
output, with no significant differences between groups. No significant differences in 
reaction times were seen between caffeine and placebo conditions. Interestingly, 31% of 
subjects exhibiting the CC allele exhibited nervousness following caffeine ingestion, 
while none of the subjects in the AA experienced an increase in nervousness. The authors 
concluded that although caffeine ingestion improved Wingate performance, the effects do 
not appear to be dependent on CYP1A2 genotype.  
Soares et al. (2018) 
The purpose of this study was to examine if the influence of CYP1A2 genotype 
on the blood pressure response to caffeine ingestion was affected by physical activity 
status and habitual caffeine consumption. Subjects were classified as fast metabolizer 
(AA genotype) or slow metabolizer (AC) based on their CYP1A2 genotype. Subjects 
were also stratified based on their physical activity level (i.e. sedentary or physically 
active) and habitual caffeine consumption (i.e. non-habitual or habitual). Results showed 
that those classified as slow-metabolizers had increased basal diastolic blood pressure 
and post-caffeine systolic blood pressure compared to fast-metabolizers. Additionally, 
physical activity only modulated the acute blood pressure responses to caffeine in slow-
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metabolizers. Further, results showed a significant increase in diastolic blood pressure of 
heavy caffeine users only in those classified as slow metabolizers. These results lead the 
authors to conclude that basal and post-caffeine blood pressure responses are modified by 
physical activity and habitual caffeine usage.  
Womack et al. (2012) 
The purpose of this investigation was the determine the influence of a (C/A) 
single nucleotide polymorphism at intron 1 of the cytochrome P450 (CYP1A2) genotype 
on 40-kilometer time trials on a cycle ergometer in trained male cyclists following acute 
caffeine (6 mg/kg/bw) supplementation. Caffeine resulted in a significantly greater 
reduction in time trial performance in the AA homozygous group, when compared to C 
carriers. The authors concluded that caffeine may have a greater ergogenic effect in AA 
allele carriers, when compared to those with a C allele.  
2.2 Neuromuscular Responses to Caffeine 
Bazzucchi et al. (2011)  
The purpose of this investigation was to examine the effects of caffeine on 
neuromuscular function during elbow flexion exercise. Fourteen male subjects 
volunteered to participate in this randomized, repeated measures, double-blind (6 
mg/kg/bw of caffeine or placebo) investigation. Maximal voluntary strength, evoked 
maximal twitch and maximal isokinetic contractions of the elbow flexor musculature was 
measured both before and after each condition. The results of this investigation found an 
enhancement in the torque-angular velocity curve, along with an 8.7% increase in 
conduction velocity, following caffeine supplementation. Additionally, the authors found 
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a significant increase in peak torque and area under of the curve of a maximal twitch 
following caffeine, when compared to placebo. The authors concluded that caffeine 
improves performance during maximal dynamic contractions of the elbow flexor 
musculature. The authors also hypothesized that caffeine has an effect on motor unit 
recruitment, as evidenced by the increase in conduction velocity seen post caffeine 
supplementation.  
Behrens et al. (2015a) 
The purpose of this study was to examine the effects of caffeine (8 mg/kg/bw) on 
maximal voluntary strength and voluntary activation of the quadriceps musculature 
during isometric, concentric and eccentric muscle actions. Further, surface 
electromyography, h-reflex and v-wave were measured. Fourteen subjects volunteered to 
participate in this randomized, controlled, counterbalanced, double-blind cross over 
design in which neuromuscular function was assessed prior to and 1-hour following 
either caffeine or placebo ingestion. The authors found a significant increase in maximal 
voluntary strength in all contraction types, along with an increased voluntary activation, 
following caffeine supplementation. The authors also found an increase in explosive 
voluntary strength and voluntary activation at the onset of contraction following caffeine 
administration. The authors concluded that while caffeine does not appear to alter spinal 
reflexes, the increases in maximal voluntary strength are most likely due to increases in 





Behrens et al. (2015b) 
The authors aimed to examine the effects of acute caffeine supplementation on 
neuromuscular function of the plantar flexors. Thirteen subjects volunteered to participate 
in this randomized, controlled, counterbalanced, double-blind investigation, in which rate 
of torque development, maximal voluntary isometric torque, h-reflex, v-wave, and neural 
drive were measured prior to and one-hour post caffeine supplementation. No change in 
evoked potentials or maximal voluntary torque were seen between conditions. However, 
the authors reported an enhanced neural drive to the plantar flexors, along with an 
increase in rate of torque development in the 0-100 ms and 100-200 ms windows 
following caffeine administration. The authors concluded that only caffeine 
supplementation increased explosive voluntary strength through enhanced neural 
activation.  
Fimland et al. (2010) 
The purpose of this investigation was to examine the effect of caffeine on 
recovery following intermittent, fatiguing isometric contractions of the plantar flexors. 
Electromyography, maximal voluntary strength, and evoked v-waves of the 
gastrocnemius and soleus were measured in 13 males prior to, immediately following, as 
well as 10 and 20 minutes following fatigue after the ingestion of either caffeine (6 
mg/kg/bw) or placebo. Following both caffeine and placebo conditions, there was a 
substantial reduction in strength with a gradual return towards baseline in the latter time 
points, with no significant differences between conditions in any measure at any time 
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point. The authors concluded that caffeine does not offer enhanced recovery following 
intermittent, fatiguing isometric contractions of the plantar flexors.  
Greer et al. (2006) 
The purpose of this investigation was examine the effects of caffeine on Wingate 
performance and neuromuscular parameters following either placebo or caffeine (5 
mg/kg/bw). Eighteen young males volunteered to participate in this investigation. Peak 
power, mean power, and percent decline, as well as surface electromyographic 
parameters of the vastus lateralis and gastrocnemius were measured. The authors found 
no significant differences in peak power, mean power, and percent decline during the 
Wingate test in either condition. Furthermore, the authors found a significant decrease in 
mean and median power frequency of both muscles in all trials, with no significant 
differences seen between conditions. The authors concluded that caffeine 
supplementation does not improve neuromuscular drive, frequency of decline in 
electromyography, and power output variables, when compared to placebo.  
Kalmar and Cafarelli (1999) 
The purpose of this investigation was to examine the effects of caffeine on 
neuromuscular function of the plantar flexors. Eleven males completed 3 conditions: 
control, placebo, or caffeine (6 mg/kg/bw), in which surface electromyography was 
collected during h-reflex of the tibial nerve, voluntary activation through the interpolated 
twitch technique, a maximal voluntary strength test, 6 submaximal isometric 
contractions, and a submaximal isometric contraction to fatigue at 50% of the subject’s 
max. Additionally, intramuscular recordings of motor unit behavior were collected during 
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the submaximal contractions. The authors found an increase in voluntary activation 
during maximal voluntary contractions, with no change in h-reflex, force-
electromyographic relationship, or motor unit behavior. Time to fatigue was significantly 
increased during the caffeine trial, with no significant change during either the control or 
placebo conditions. Interestingly, the authors reported that the increased time to fatigue 
was accompanied by an attenuated decline in twitch amplitude during the caffeine 
condition. The authors concluded that the increase in maximal strength was most likely 
due to supraspinal factors, while the lack of decline in twitch amplitude following fatigue 
was most likely due to a peripheral mechanism.  
Kalmar and Cafarelli (2004) 
 The purpose of this study was to examine if the fatigue-related decline in surface 
electromyography and motor evoked potentials could be attributed to central mechanisms 
and if so, if this could be offset by caffeine supplementation. Seven volunteers underwent 
two experimental conditions (6 mg/kg/bw of caffeine or placebo), in which central 
excitability was measured via transcranial magnetic stimulation and surface 
electromyography, voluntary activation was measured via twitch interpolation before, 
during, and after fatigue, and a maximal m-wave was elicited to monitor peripheral 
transmission. The fatiguing protocol of the first dorsal interosseous consisted of 4 sets of 
10 finger abductions at 75% of the subject’s max, with 2 seconds of rest between 
contractions and 12 seconds between sets. The authors reported an increase post-
activation potentiation of the motor evoked potentials following caffeine administration, 
with a decline in motor evoked potential, maximal electromyography, and peripheral 
transmission with fatigue in both conditions. The authors stressed that the estimates of 
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central fatigue were greatly reduced when normalized to maximal m-wave, thus, when 
estimating central fatigue, peripheral transmission must be accounted for. The authors 
concluded that caffeine may induce increases in post-activation potentiation and could 
provide utility in the measure of central fatigue.  
Kalmar and Cafarelli (2006) 
The purpose of this investigation was to examine whether declines in central 
excitability contribute to the central fatigue post exercise and if this potential decrease in 
central excitability could be counteracted with caffeine supplementation. Eight men 
completed two experimental sessions in which knee extensor torque, voluntary activation, 
peripheral transmission, contractile properties, and central excitability were measured 
prior to and after caffeine (6 mg/kg/bw) or placebo following an initial hour of rest. 
Finally, a fatigue protocol consisting of sets of 10 4-s knee extension contractions, in 
which the first and last contraction were maximal and the middle 8 were 50% of max, 
was completed until a 35% drop in maximal voluntary torque was seen. The authors 
found a significant increase in central excitability, as exhibited by an increased pre-
fatigue motor evoked potential and cortically evoked twitch, following caffeine 
administration. The authors also found that caffeine potentiated the motor evoked 
potential early in the fatigue protocol and offset the sharp decline seen in the placebo 
condition. However, this was not associated with an increased voluntary activation during 
fatigue or recovery. The authors thus concluded that caffeine improves central 




Kalmar et al. (2006)  
The purpose of this investigation was to examine the potential role of reduced 
spinal excitability in central activation failure and if this reduction could be mediated by 
acute caffeine supplementation. Ten male subjects volunteered to participate in two 
experimental sessions (6 mg/kg/bw of caffeine or placebo), in which contractile and 
electrical properties of the plantar flexors. Spinal excitability was measured as the ratio of 
h-reflex to maxima m-wave, while voluntary activation maximal electromyography and 
interpolated twitch. Both conditions saw a significant reduction in maximal voluntary 
strength and voluntary activation. However, caffeine offset the reduction in spinal 
excitability observed during the placebo condition. Interestingly, the decline in spinal 
excitability was correlated with a decline in maximal electromyography amplitude, but 
not with decline in maximal voluntary strength or voluntary activation. The authors 
concluded that the decline in spinal excitability did not limited maximal activation of the 
plantar flexors following a fatiguing protocol.  
Lopes et al. (1983) 
The purpose of this investigation was to examine the effects of caffeine on 
voluntary and electrically stimulated contractions of the adductor pollicis muscle. Five 
healthy adults completed a series of voluntary and electrically evoked contractions prior 
to and immediately after caffeine (500 mg) and placebo. The authors reported no 
difference in maximal voluntary strength prior to either supplement. However, in fresh 
muscle and after fatigue, the authors reported higher muscle tensions at lower frequency 
stimulation following caffeine supplementation, resulting in a leftward shift of the 
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frequency-force curve. The authors concluded that 500 mg of caffeine alters muscle 
contractile properties in both a fresh and fatigued state.  
Meyers and Cafarelli (2005)  
The purpose of this investigation was to examine whether the previously reported 
increase in time to task-failure following caffeine supplementation was a function of 
increased firing rates of active motor units. Ten male volunteers completed a fatigue 
protocol consisting intermittent quadriceps contractions at 50% of maximal strength 1-
hour after the ingestion of either caffeine (6 mg/kg/bw) or placebo, in a randomized, 
double-blind, repeated-measures design. The authors found a significant increase in time 
to fatigue in the caffeine condition, when compared to placebo. However, this increase 
could not be explained by increase motor unit firing rates or other neuromuscular 
parameters. Interestingly, in the caffeine condition, the amplitude of evoked twitches and 
their maximal instantaneous firing rate of relaxation did not decline to the same degree as 
the placebo condition. The correlation with these variables and the increase in time to 
task-failure led the authors to suggest that caffeine effects on calcium reuptake and twitch 
force may be the primary mechanisms for increased time to fatigue following caffeine 
administration.  
Mora-Rodríguez et al. (2012)  
The purpose of this study was to examine the efficacy of caffeine to counteract 
the decline in neuromuscular performance during the morning hours associated with the 
circadian rhythm. Twelve resistance-trained males volunteered for this double-blind, 
repeated measures design in which a neuromuscular function was assessed under 3 
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conditions: 1) morning with caffeine (3 mg/kg/bw); 2) morning with placebo; 3) 
afternoon with placebo. Bar velocity during 75% 1-repetition maximum bench press and 
back squat, as well as maximal voluntary contraction strength and electrically evoked 
contractions of the right quadriceps were measured prior to and post-supplement 
consumption in each condition. Dynamic strength and power output were significantly 
enhanced in the afternoon when compared to the morning placebo condition. However, 
during the morning caffeine condition, participants exhibited significantly higher 
muscular strength and power output, with the exception of bench press velocity, then the 
morning placebo condition. Additionally, evoked measures were significantly higher in 
the morning caffeine condition, when compared to the morning placebo. The authors 
concluded that morning caffeine administration can bring neuromuscular performance to 
afternoon levels. Additionally, the authors suggested that due to the increase in evoked 
contractions, the performance increases most likely occur at the muscle level.  
Morse et al. (2016) 
The purpose of this investigation was to examine whether a low-dose of caffeine 
would delay the onset of the electromyographic fatigue threshold in the superficial 
quadriceps musculature. Ten physically actives males completed 1-hour of single-leg 
cycling in which electromyographic signals were recorded from the vastus medialis, 
vastus lateralis, and rectus femoris following either caffeine (200 mg) or placebo in a 
randomized, double-blind, repeated measures design. The authors found a significant 
increase in maximal power output and electromyographic fatigue threshold following 
caffeine, when compared to placebo. The authors concluded that acute low-dose caffeine 
supplementation delays neuromuscular fatigue during single-leg cycling.  
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Pereira et al. (2010) 
The purpose of this investigation was to examine the effects of acute caffeine 
supplementation on anaerobic performance and fatigability. Fourteen (7 males and 7 
females) recreationally active volunteers completed a Wingate test following either 
caffeine (6 mg/kg/bw) or placebo in this randomized, double-blind, repeated measures 
study. Wingate power output variables and median power frequency of the vastus 
medialis, vastus lateralis, and rectus femoris were recorded during the testing. The results 
of the investigation showed no improvement in relative peak power, relative mean power, 
fatigue index, or peak power instant, nor in median power frequency of any quadriceps 
muscle. The authors concluded that caffeine offered no benefit to the Wingate 
performance parameters measured in the present investigation.  
Pethick et al. (2018) 
The purpose of this investigation was to examine the effects of acute caffeine 
consumption of muscle torque complexity of the knee extensors. Sixty minutes after 
caffeine consumption (6 mg/kg/bw) or placebo, 11 healthy participants completed 
intermittent (6 s. work/4 s. rest) isometric contractions at 50% of their maximal voluntary 
torque in this randomized, double-blind, repeated measures design. Torque complexity 
and fractal scaling of the torque were measured throughout the fatigue protocol and 
global, central, and peripheral fatigue (through peripheral nerve stimulation) were 
measured prior to and immediately post-fatigue. Caffeine significantly increased time to 
fatigue and complexity significantly decreased as global, peripheral, and central fatigue 
developed in both conditions. Interestingly, the rate of decrease in complexity, as well 
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and the rate of development of central and global fatigue were significantly slower 
following caffeine supplementation. However, there were no differences in the rate of 
peripheral fatigue between conditions. The authors concluded that caffeine delayed the 
accumulation of fatigue and loss of torque complexity leading to an increase in time to 
task-failure, which are most likely due to centrally-mediated mechanisms.  
Pires et al. (2018)  
The purpose of this investigation was to examine the effect of caffeine and 
caffeine-perceived placebo on motor performance during a maximal incremental cycling 
test. Nine participants completed three incremental cycling tests (control, placebo, or 
caffeine) in a randomized, double-blind, repeated measures design 60 minutes following 
the ingestion of the substance. Prefrontal cortex oxygenation, motor cortex activation and 
vastus lateralis and rectus femoris muscle activity were measured throughout each test. 
Both placebo and caffeine significantly increased rectus femoris muscle activity at 
maximal effort and enhanced peak power output and time to exhaustion, when compared 
to control. At 80% and 100% duration of the test, both placebo and caffeine exhibited 
increase prefrontal cortex deoxygenation, but not motor cortex activation, when 
compared to control. The authors concluded that both caffeine and a caffeine-perceived 
placebo can improve motor performance, despite the lack of change in motor cortex 
activation and a decrease in prefrontal cortex deoxygenation.  
Plaskett and Cafarelli (2001) 
The purpose of study was to examine the effects of caffeine on neuromuscular 
parameters during submaximal isometric contractions. In a randomized, double-blind, 
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repeated measures design, 15 subjects completed repeated 50% maximal effort isometric 
contractions of the knee extensors to failure 1-hour following the ingestion of caffeine (6 
mg/kg/bw) or placebo. Time to task-failure was significantly increased after caffeine 
when compared to placebo. Interestingly, changes in contractile properties of the 
quadriceps, motor unit activation and m-wave amplitude could not account from the 
changes seen with caffeine administration. The authors reported a reduced “force 
sensation” during the first 10-20 second of the contraction in the caffeine condition, when 
compared to placebo. The authors thus suggested that caffeine exerts its effects due to 
neural factors and stated the increase in time to task-failure may have been caused by “a 
willingness to maintain near-maximal activation longer because of alterations in muscle 
sensory processes.”   
Walton et al. (2002) 
The purpose of this study was to examine the effect of caffeine on the self-
sustained firing of motor units of the tibialis anterior. Seven caffeine naïve male ingested 
either caffeine (6 mg/kg/bw) or placebo in this randomized, double-blind, repeated 
measures study. Maximal voluntary contractions, surface electromyography and 
intramuscular motor unit recordings were recorded prior to and 1-hour following the 
ingestion of each supplement. The authors found a significant increase in the occurrence 
of self-sustained firing of motor units in the tibialis anterior following caffeine ingestion.  
Walton et al. (2003) 
The purpose of this investigation was to examine whether acute caffeine ingestion 
would cause an increase in spinal excitability and h-reflex amplitude. Seven subjects 
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completed 2 experimental visits in this double-blind, randomized, repeated measures 
design. An h-reflex recruitment curve was recorded through tibial nerve stimulation 
immediately prior to and 1-hour post-caffeine (6 mg/kg/bw) or placebo ingestion. The 
authors found a significant increase in the slope of the h-reflex (normalized to m-wave) 
following caffeine administration. The author thus concluded that caffeine can effectively 








3.1 Participants  
Forty-two young, healthy males completed the entire study protocol and were 
genotyped for CYP1A2 enzyme. Subjects were then classified as AA (FAST: n = 26) or 
AC/CC (SLOW; n =16). Table 1 contains the data for descriptive statistics (presented as 
mean ± (SD), along with the results of the independent samples t-tests. All participants 
voluntarily participated in each testing session, which took place in the Applied 
Neuromuscular Physiology Laboratory at Oklahoma State University. This study was 
approved by the Oklahoma State University Institutional review board for human 
participant research (Approval #: ED-17-88) prior to any data collection. Prior to any 
testing, all participants completed an informed consent, pre-exercise health questionnaire, 
caffeine consumption questionnaire, and a brief exercise history survey to quantify their 
habitual caffeine consumption and physical activity. Participants were included in the 
study if they met the inclusion criteria and were free from any musculoskeletal 
dysfunctions or circulatory/edema pathologies involving the hip, knee, or ankle joints. 
Participants also reported being free from any neurological disorders. 
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 FAST SLOW Sig. 
Age  22 ± 3 yrs 24 ± 4 yrs p = 0.204 
Height  176.0 ± 6.8 cm 179.6 ± 5.0 cm p = 0.075 
Weight  89.0 ± 15.0 kg 87.0 ± 10.6 kg p = 0.653 
Avg. Caffeine Intake 290.6 ± 295.1 mg/day 324.7 ± 276.3 mg/day P = 0.715 
Table 1. Mean ± SD and p-values for descriptive variables between CYP1A2 genotype 
groups.  
3.2 Experimental Design  
This study consisted of 3 separate visits to the laboratory, a familiarization session 
and 2 experimental sessions. The familiarization session lasted approximately 1 hour, 
while each experimental session lasted approximately 3 hours. Each experimental session 
was separated by 6 ± 1 days and took place at approximately the same time of day (±1 
hour).  Additionally, every effort was made to begin experimental sessions in the 
morning, as caffeine has been shown to have potentially dampened ergogenic effects in 
the afternoon (Pataky et al. 2016). Participants were instructed to refrain from any 
structured lower body exercise 48 hours prior to each testing session and abstain from 
caffeine consumption throughout the duration of their enrollment in the study (i.e. 2 
weeks)., Thus participants were withdrawn from caffeine for a minimum of 5 days prior 
to the first experimental visit. On the first visit, following the explanation of all study 
procedures, the signing of the informed consent and the completion of the required 
paperwork, the participant’s height and weight were measured. Each participant was then 
seated in the dynamometer and completed several practice contractions required during 
future testing sessions, which upon completion, completed the familiarization session. 
For each experimental condition, participants were instructed to arrive at the laboratory in 
a fasted state. Upon arrival, participants were instructed to lie in a supine position for 5 
minutes. Following this 5-minute period, body composition was measured via 
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Bioelectrical Impedance Spectroscopy (BIS; ImpediMed, Inc., Carlsbad, CA, USA) in 
order to quantify each individual’s fat mass (FM) and fat free mass (FFM). Following the 
assessment of body composition, ultrasound (US) images of the right thigh were 
performed to quantify the size, and quality of each participant’s rectus femoris (RF) and 
vastus lateralis (VL). All body composition measures and US images were obtained 
while the participant remained in the supine position. Participants were then seated in a 
dynamometer in for all neuromuscular function assessments. Specifically, h-reflex and 
m-wave of the soleus and m-wave of the quadriceps musculature were measured via 
peripheral nerve stimulation. Evoked twitch properties of the quadriceps musculature 
were assessed in incremental steps, culminating in the measurement of the compound 
muscle action potential (CMAP). These previously mentioned evoked involuntary 
measures occurred prior to any warm-up (Folland et al. 2008). Following a brief warm-
up, subjects then performed maximal voluntary isometric contraction (MVIC) testing, in 
which the subject’s maximal voluntary torque (MVT) was recorded. Additionally, 
voluntary activation (%VA), resting doublet, and potentiated doublet twitch properties 
were assessed via the interpolated twitch technique (ITT). Finally, subjects completed 2 
MVIC ramp contractions at 30%, 50%, and 70% of their MVIC force in order to record 
motor unit (MU) behavior. Approximately 2 minutes of rest was given between each 
ramp contraction. Following the completion of neuromuscular function testing, subject’s 
consumed either 6 mg/kg/bw of caffeine anhydrous (CAF) or flour placebo (PLA), which 
was provided in gelatin capsules. Participants then remained seated in the dynamometer 
for one-hour of rest following the consumption of the supplement. One-hour post 
consumption, neuromuscular function was again completed in the manner described 
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above. Following the completion of post-consumption testing and a 5-minute washout 
period, subjects completed repeated 50% MVIC ramp contractions to fatigue, followed 
by an additional ITT to quantify fatigue. MU behavior, muscle activation and torque 
variables were analyzed during the first, middle and last repetitions of the fatigue 
protocol. Upon the completion of the fatigue protocol, the experimental visit was 
completed. Torque and electromyographic (EMG) signals were recorded continuously 
during all quadriceps measurements. Each experimental visit (i.e. CAF or PLA) was 
identical in procedures and the order was randomized for each participant. Below is a 
summary of each visit in Table 2: 




1. Body Composition 
2. Ultrasound Measures 
3. Evoked Measures of Soleus  
4. Evoked Measures of Quadriceps 
5. Voluntary Strength Measures  
6. Voluntary Activation  
7. Motor Unit Recordings 




1. Evoked Measures of Soleus  
2. Evoked Measures of Quadriceps 
3. Voluntary Strength Measures  
4. Voluntary Activation 
5. Motor Unit Recordings 
5-minutes of rest 
Fatigue Protocol (Repeated 50% MVIC contractions to fatigue ) 
Post-Fatigue  1. Voluntary Activation  






3.3 Instrumentation and Procedures 
3.3.1 Ultrasonography 
 Cross-sectional area (mCSA) and echo intensity (EI) of the right VL and RF 
musculature were obtained using a portable brightness mode (B-Mode) 
diagnosticultrasound imaging device (GE Logic S8, Milwaukee, WI, USA) with a linear 
array probe (model ML6-15-D, 4-15 MHz, 50-mm field view) via transverse images. All 
US images were taken with the participants laying on their left side on an adjustable 
padded plinth with their legs completely relaxed and knees bent at approximately 10°. All 
US images were taken at 50% of the distance between the right greater trochanter and the 
lateral femoral epicondyle. During each panoramic US scan, the probe was placed 
perpendicular to the skin and advanced laterally along the skin above the musculature in a 
slow, consistent manner, with great care taken to ensure minimal and consistent pressure. 
A generous amount of water-soluble transmission gel was applied to the skin to enhance 
acoustic coupling (Wilhelm et al. 2014). In order to maintain consistency between 
subjects and visits, the gain and frequency settings were recorded and held constant, at 50 
dB and 12Hz, respectively. Depth was also held constant between each participant and 
visit to keep the pixels per cm standardized. Panoramic US images were captured until 
three uniform scans with acceptable image quality were collected and recorded for future 
analyses (Jenkins et al. 2015b). 
A single experienced investigator performed all US scans in order to minimize the 
inter-rater variability. All recorded US images were analzyed using Image-J software 
(National Institutes of Health, USA, Version 1.50i) and were performed by a single 
experienced investigator. Each image was individually calibrated from pixels to cm using 
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the straight-line function available in Image-J. VLmCSA, VLEI, RFmCSA, and RFEI of the 
three images were analyzed by defining a region of interest by including as much muscle 
as possible, without including any bone or fascia, using the polygon function available in 
the Image-J software. EI for each muscle was quantified using computer-aided gray scale 
analysis using the standard histogram function and was recorded in arbitrary units (au) 
with values ranging from 0 (black) to 255 (white). All VLmCSA, VLEI, RFmCSA, and RFEI 
were recorded, stored, and used in the final analysis. 
3.3.2 Evoked Measures  
Evoked measures of the quadriceps and soleus musculature were assessed in the 
present investigation. During all testing, participants were seated with straps securing the 
trunk and hips on a calibrated isokinetic dynamometer (Biodex System 4; Biodex 
Medical Systems, Inc. Shirley, NY, USA) with the axis of rotation of the dynamometer 
head aligned with the lateral epicondyle of the subject’s right femur. For all quadriceps 
muscle actions, the lower right leg was secured to the dynamometer lever arm 
approximately 3 cm above the lateral malleolus. Additionally, all participant’s hip and 
knee angle was held constant at approximately 90° and 120°, respectively, which was 
held constant throughout all testing. 
Maximal M-wave of the soleus (SOLM) musculature was assessed via 
transcutaneous electrical stimulation of the tibial nerve. Briefly, the stimuli were 
delivered via a cathode-anode arrangement using high voltage (maximal voltage = 400 V) 
stimulus from a constant-current electrical stimulation cart (Cadwell Sierra Summit, 
Cadwell Industries, Inc., Kennewick, WA, USA). The anode and cathode of the probe 
(Cadwell Stimtroller Plus, Cadwell Industries, Inc., Kennewick, WA, USA) were placed 
37 
 
on either side of the tibial nerve, with a recording electrode placed on the muscle belly of 
the soleus, a reference electrode on the Achilles tendon, and a ground electrode on the 
medial malleolus. The optimal stimulation probe position was determined by delivering 
single low-voltage exploratory stimuli (20-30 mV) with the cathode probe. Final probe 
location was selected based on visual inspection of the CMAP amplitudes. Once the 
optimal probe position was obtained, the spot was marked with permanent marker and 
used for both SOLM and soleus h-reflex (SOLH) assessments. This mark was maintained 
throughout the duration of the investigation to obtain consistent probe placement across 
visits. For all m-wave assessments, incremental increases in intensity were made until a 
plateau in the CMAP was found. Following the successful measurement of the CMAP, a 
baseline measure where no m-wave was present was located and recorded. Once this was 
recorded, a step-wise increase (i.e. 5 mV) from baseline back to CMAP was completed in 
order to obtain a recruitment curve for each subject. The muscle activation and the torque 
produced by each incremental evoked twitch were recorded. Following the CMAP 
plateau, two supramaximal (i.e. 120% of maximal CMAP stimulation) stimulations were 
delivered, if possible. Throughout the duration of the protocol, 10 seconds were given 
between each stimulation to ensure complete neuromuscular recovery. The mean m-wave 
peak-to-peak (MMAX) amplitude of the two stimulations was defined as the maximal m-
wave or SOLM. SOLM was used for the normalization of the voluntary EMG variables 
and SOLH.  
Following the completion of the SOLM assessment, SOLH was assessed in a 
similar manner. Briefly, the subject was seated and relaxed in the dynamometer, with 
their head resting on the cushion and eyes closed to further facilitate the reflex. The 
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polarity of the probe was reversed and stimulation width increased to 1k. Incremental 
increases in stimulation were applied to the tibial nerve until a maximal SOLH was 
achieved, as visually observed in real time. An additional SOLM was then measured and 
recorded. M-wave of the RF (RFM) and VL (VLM) were then assessed via transcutaneous 
electrical stimulation of the femoral nerve, with the procedures remaining consistent from 
the SOLM. The recording electrode was placed on the belly of the VL, with the reference 
electrode on the distal quadriceps tendon and the ground electrode remaining on the 
medial malleolus. However, RFM, VLM, and EMG variables were recorded through 
separate bipolar electrodes (discussed further in section 3.3.4). Torque and EMG were 
recorded continuously throughout the protocol and further analyzed offline The cathode 
of the probe was placed in the femoral triangle, with the anode (40 x50mm, Technomed 
Medical Accessories, Amerikalaan 71, Netherlands) on the greater trochanter of the right 
femur. The placement of the cathode was marked with permanent marker in order to 
ensure consistent placement between visits  
Evoked twitch properties measures included resting peak twitch torque (pTT), 
resting peak rate of twitch torque development (+dt/dt), resting peak rate of twitch 
relaxation (-dt/dt), resting doublet peak twitch torque (pTTD), potentiated doublet peak 
twitch torque (pTTPOT), resting doublet peak rate of twitch torque development (+dt/dtD), 
potentiated double peak rate of twitch torque development (+dt/dtPOT), resting doublet 






3.3.3 Maximal Strength and Voluntary Activation  
 For all voluntary isometric testing, participants were seated with straps securing 
the trunk, and hips on a calibrated isokinetic dynamometer with the axis of rotation of the 
dynamometer head aligned with the lateral epicondyle of the subject’s right femur, with 
the lower right leg was secured to the dynamometer lever arm approximately 3 cm above 
the lateral malleolus. Each participant’s hip and knee angle were held constant at 120°, 
respectively, which were held constant throughout all testing. Participants completed a 
submaximal isometric warm-up by performing 3, 3-second contractions at 25%, 50%, 
and 75% of their perceived effort, with approximately 30 seconds of rest between 
contractions. Following the warm up and 1 minute of rest, 2 separate 3-5 second MVICs 
of the knee extensors were performed. One minute of rest was given between each 
attempt in order to avoid any undue fatigue. For each MVIC contraction, the participant 
was instructed to kick out “as hard as possible” during the entire contraction (Tomko et 
al. 2018). MVT was defined as the highest instantaneous torque produced during a 1000 
ms epoch of the MVIC contractions and recorded to normalize force during the MU ramp 
contractions. 
Finally, an additional MVIC was performed in order to assess %VA via ITT. 
Specifically, prior to the contraction, a doublet stimulus was applied to the femoral nerve 
in order to obtain a resting doublet twitch. The subject then completed an MVIC, in 
which another doublet stimulus was applied during the force plateau of the contraction 
(i.e. ITT), with an additional doublet stimuli applied 3 to 5 seconds following the 
completion of the contraction (i.e. potentiated twitch). %VA was calculated as (1- 
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[superimposed twitch/potentiated twitch])*100 (Behm et al. 1996). Loud verbal 
encouragement was given during each voluntary contraction.   
3.3.4 Surface Electromyography 
 Surface EMG signals were collected from bipolar bar electrodes (Delsys, Inc., 
Natick, MA, USA) placed over the VL and RF of the right leg using a 16-channel 
Bagnioli acquisition system (Delsys, Inc., Natick, MA, USA). EMG variables analyzed 
included normalized (to VLM) EMG amplitude (VLAMP), VL median power frequency 
(VLMDF), VL integrated EMG (VLiEMG), normalized (to RFM) EMG amplitude (RFAMP), 
RF median power frequency (RFMDF) and RF integrated EMG (RFiEMG). Additionally, 4 
channels of EMG were recorded from a specialized five-pin array that was placed over 
the distal portion of the VL in accordance with the recommendations set forth by Zaheer 
et al. (2012). In order to minimize skin impedance and improve signal quality, the skin 
was shaved, abraded and cleansed with isopropyl alcohol prior to the placement of the 
surface electrodes (Beck and Housh 2008). Each sensor was secured to the skin with 
hypoallergenic tape directly and was placed over the muscle belly in line with the muscle 
fiber orientation in a bipolar fashion (Lieber and Friden 2000) in accordance with 
SENIAM guidelines (Hermens et al. 1999). A reference electrode (Dermatrode; 
American Imex, Irvine, CA, USA) was placed over the spinous C7 process. All sensor 






3.3.5 Motor Unit Decomposition 
MU behavior was recorded through the 4 channels of raw EMG signal recorded 
from the 5-pin array placed over the distal portion of the VL. In order to record MU 
behavior, isometric ramp contractions were completed in a randomized order at 30%, 
50%, and 70% of each subject’s previously recorded MVT. Two contractions were 
completed at each intensity and 2 minutes were given between each contraction to 
minimize the effects of fatigue. Each contraction featured a 10% MVT/s ramp up to the 
target torque level, a hold at the target torque, and a 10% MVT/s ramp down to baseline 
(Colquhoun et al. 2018b). All recorded signals were stored on a personal computer and 
decomposed offline using the Precision Decomposition III Algorithm first described by 
De Luca et al. (2006) and improved upon by Nawab et al. (2010). Following the 
decomposition process, only MUs demonstrating at least 90.0% accuracy, as determined 
by the Decompose-Synthesize-Decompose-Compare test, were retained and utilized in 
the final analyses. Additionally, as the purpose of these recordings was to characterize 
MU behavior at rest, all MUs recruited during the plateau of the contraction were 
excluded from final analysis (Miller et al. 2019). Finally, only contractions following the 
recommendations set forth by Colquhoun et al. (2018b) were utilized in the final 
analyses.  
All MU firing rate curves were smoothed prior to calculation by low-pass filtering 
each MUs impulse train with a 2-second Hanning window. Custom-written LabVIEW 
programs were used to analyze all of the MUs that met the inclusion criteria described 
previously. The MU properties calculated by the LabVIEW programs from each 
contraction were those previously described by Colquhoun et al. (2018a; 2018b). 
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Specifically, these variables included: [1] Recruitment threshold (RT), which is defined 
as the relative force (% MVIC) at which the MU first discharged; [2] Mean firing rate 
(MFR), which was calculated of as the average firing rate (pulses·s-1 (pps)) during the 
plateau in each individual MU’s firing curve; and [3] MU action potential amplitude 
(MUAP) , defined as the average peak-to-peak amplitude (mV) of the waveforms across 
the 4 EMG channels. MU behavior was expressed as a function of RT and MUAP. For 
the MFR vs. RT relationship, linear regression was utilized (Colquhoun et al. 2018a; 
Colquhoun et al. 2018b). For all other relationships, exponential regressions were run 
(Miller et al. 2019). 
3.3.6 Fatigue Protocol  
During both experimental conditions, subject’s completed an isometric fatigue 
protocol consisting of repeated 50% MVT isometric ramp contractions until failure. Each 
ramp contraction began and ended with a 3 second quiescent period, with a 5 second 
ramp to target torque, a 10 second hold at target torque, and a 5 second ramp back to 
baseline. Contractions were repeated until the subject if not longer able to maintain at 
least 45% of MVT for at least 80% of the plateau (Pethick et al. 2018). During the 
fatiguing exercise protocol, average torque (TQAVG), standard deviation of torque (TQSD), 
coefficient of variation of torque (TQCV), and torque impulse (TQIMP) were quantified.   
3.4 Torque and EMG Signal Processing 
EMG and Torque signals were recorded simultaneously during all voluntary and 
evoked isometric contractions of the quadriceps described previously and analyzed using 
custom-written LabVIEW programs (LabVIEW 2017; National Instruments, Austin, TX, 
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USA). The torque and EMG signals were preamplified with a common mode rejection 
ratio of 110 dB min and an impedance of 2M Ω and sampled at 20 kHz with through the 
Bagnioli acquisition system. The signals were zero-meaned and digitally filtered using a 
zero-phase shift 4th-order Butterworth filter with a band pass of 10 – 499 Hz. The torque 
signals were zero-meaned, low-pass filtered using a zero-phase shift 4th-order 
Butterworth filter with a 15 Hz cutoff. Torque and EMG onset were manually detected 
from the filtered signals to provide a more accurate analysis of torque and EMG variables 
(Folland et al. 2014; Tillin et al. 2013). All onsets were manually determined by the same 
investigator to avoid inter-rater reliability bias. Further, all recorded signals were stored 
on a personal computer and processed off-line with a custom written LabVIEW program. 
All analyses were completed using only filtered signals. 
3.5 Saliva Analysis  
Saliva samples were collected from each participant on the last experimental visit 
to quantify their CYP1A2 genotype, among others. Saliva samples were collected using 
an Oragene ON-500 saliva collection kit (DNA Genotek, Ottawa, Ontario, Canada) for 
DNA analysis. All DNA samples were shipped to the University of Toronto for analysis 
and were stored at -80⁰C until final analyses. Briefly, genotyping was performed using 
the iPLEX Gold assay with mass-spectrometry-based detection on the Sequenom 
MassARRAY® platform (Agena Bioscience, San Diego, CA, USA) as previously 
described by Guest et al. (2018). Further detail on DNA analysis can be found in Jenkins 




3.6 Statistical analysis 
 Descriptive statistics of the participants are displayed in Table 1 as means ± 
standard deviations to describe the between-subject variability. Body composition and 
US measures for individual subjects were averaged across days and independent samples 
t-tests were run to quantify and potential differences between genotypes. All statistical 
analysis was performed using SPSS v. 24 (SPSS Inc., Armonk, New York, USA) and the 
type-I error rate was set a-priori at 5%.   
 Separate two (Condition) x 2 (Time) x 2 (Genotype) mixed-model anaylsees of 
variances (ANOVs) were run to examine resting changes in MVT, SOLM, SOLH, RFM, 
VLM, %VA, pTT, +dt/dt, -dt/dt, pTTD, pTTPOT, +dt/dtD, +dt/dtPOT, -dt/dtD, -dt/dtPOT, 30% 
MFR vs. RT slope, 30% MFR vs. RT y-intercept, 30% MUAP vs. RT A term, 30% 
MUAP vs. RT b term, 30% MFR vs. MUAP A term, 30% MFR vs. MUAP b term, 50% 
MFR vs. RT slope, 50% MFR vs. RT y-intercept, 50% MUAP vs. RT A term, 50% 
MUAP vs. RT b term, 50% MFR vs. MUAP A term, 50% MFR vs. MUAP b term, 70% 
MFR vs. RT slope, 70% MFR vs. RT y-intercept, 70% MUAP vs. RT A term, 70% 
MUAP vs. RT b term, 70% MFR vs. MUAP A term, and 70% MFR vs. MUAP b term. 
Additionally, separate 2 (Condition) x 2(Time) x 2 (Genotype) mixed-model ANOVAs 
were utilized to examine potential changes from post-supplementation to post-fatigue in 
%VA, pTTD, pTTPOT, +dt/dtD, +dt/dtPOT, -dt/dtD, and -dt/dtPOT..In order to quantify 
changes during the fatiguing protocol at the first, middle, and last repetition, separate 2 
(Condition) x 3 (Time) x 2 (Genotype) mixed-model ANOVAs were run to analyze 
TQAVG, TQSD, TQCV, TQIMP, VLiEMG, VLMDF, VLAMP, RFiEMG, RFMDF, RFAMP, MFR vs. 
RT slope, MFR vs. RT y-intercept, MUAP vs. RT A term, MUAP vs. RT b term, MFR 
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vs. MUAP A term, and MFR vs. MUAP b term.  Significant interactions were 
decomposed with follow up, lower-order ANOVAs and Sidak corrected dependent 
samples t-tests on the simple main effects.  Simple main effects that were not involved in 
the interaction were analyzed with Sidak corrected dependent samples t-tests on the 
marginal means. Finally, simple linear regression analyses were performed to quantify 
the relationship between twitch variables and change in MVIC across conditions. The 








4.1 Body Composition & Ultrasonography  
Table 3 presents the body composition and US data, along with the results of the 
independent samples t-tests. All data are presented as mean ± SD. 
 FAST SLOW Sig. 
Rectus Femoris Cross-Sectional Area (RFmCSA) 11.6 ± 3.2 cm
2 11.8 ± 1.9 cm2 p = 0.852 
Rectus Femoris Echo Intensity (RFEI)  37.9 ± 5.3 au 40.6 ± 5.3 au p = 0.115 
Vastus Lateralis Cross-Sectional Area (VLmCSA)_ 35.3 ± 5.1 cm
2 32.4 ± 9.0 cm2 p = 0.179 
Vastus Lateralis Echo Intensity (VLEI)  45.6 ± 7.3 au 50.2 ± 5.0 au p = 0.032* 
Fat-Free Mass (FFM) 73.6 ± 10.1 kg 75.1 ± 8.3 kg p = 0.635 
Fat Mass (FM) 14.2 ± 8.4 kg 17.7 ± 8.8 kg p = 0.213 
Table 3. Mean ± SD and p-values for ultrasound and body composition measures 
between genotype groups.  
*Indicates significant difference between groups  
 
The results of the independent samples t-tests indicated a significantly higher VLEI in 
SLOW when compared to FAST (50.2 ± 5.0 au vs. 45.6 ± 7.3 au; p = 0.032). 
4.2  Neuromuscular Function: Pre vs. Post Supplementation 
The following results represent data examining changes in neuromuscular function 
prior to- (PRE) and 1-hour following (POST) caffeine (CAF) and placebo (PLA) 
supplementation.  Neuromuscular changes associated with the fatiguing exercise protocol 
are discussed later in the section 4.3. 
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4.2.1 Maximal Voluntary Isometric Contraction (MVIC) Strength   
A significant Condition × Time interaction (F1,37 = 7.563; p = 0.009; η
2 = 0.170) 
was observed. Follow-up analyses indicated that there was a significant decrease in 
MVIC strength from PLAPRE to PLAPOST (295.6 ± 65.2 Nm vs. 268.7 ± 73.5 Nm; p = 
<0.001), but not from CAFPRE to CAFPOST (295.7 ± 68.9 Nm vs. 286.6 ± 75.4 Nm; p = 
0.094). There were no other main effects or interactions (all p > 0.05). This data is 
visually depicted below in Figure 1 
. 
Figure 1. Individual plots of Maximal Voluntary Torque (MVT) obtained during 
Maximal Voluntary Isometric Contractions (MVIC) prior to and following caffeine 
(CAF) and placebo (PLA) ingestion. The orange bars represent the mean MVT during 
each condition.  
*Indicates significant decrease in MVT from PLAPRE to PLAPOST (p = <0.001). 
 
4.2.2 Motor Unit (MU) Behavior  
The following results represent data examining the relationship between mean 
firing rate (MFR), recruitment threshold (RT), and MU action potential (MUAP) 
amplitude at PRE and POST in each condition. Twenty-six subjects met the MU criteria 
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for all 3 contraction intensities and were utilized in the following analyses. The genotype 
breakdown was: FAST (n = 15) and SLOW (n = 11). Changes in MU behavior during the 
fatiguing exercise protocol will be discussed separately in section 4.2.1.  
4.2.2.1 30% MVIC  
The p-values for the main and interaction effects from each of the ANOVAs for 
the relationships used to characterize MU behavior at 30% MVIC can be found below in 
Table 4. The average number of MUs analyzed per subject were: CAFPRE: 20.9 MUs 
(95% CI: 18.7-23.2 MUs), CAFPOST: 22.2 MUs (95% CI: 20.1-24.2 MUs), PLAPRE: 21.0 
MUs (95% CI: 18.8-23.2 MUs), and PLAPOST: 21.9 MUs (95% CI: 19.9-23.9 MUs). The 
mean RT range (% MVIC) for analyzed MUs were: CAFPRE: 4.9-23.5%, CAFPOST: 6.7-
25.1%, PLAPRE: 5.2-24.4%, and PLAPOST: 5.6-25.3%. Significant main and interaction 
effects are discussed below.  
 MFR vs. RT MUAP vs. RT MFR vs. MUAP 
 Slope Y-Int A b A b 
Condition 0.231 0.986 0.474 0.192 0.297 0.336 
Condition x Genotype 0.290 0.646 0.033* 0.254 0.432 0.427 
Time 0.627 0.758 0.492 0.280 0.356 0.748 
Time x Genotype 0.951 0.680 0.626 0.924 0.836 0.325 
Condition x Time 0.055 0.063 0.134 0.172 0.895 0.574 
Condition x Time x Genotype 0.573 0.676 0.139 0.530 0.825 0.574 
Genotype 0.737 0.652 0.094 0.491 0.245 0.273 
Table 4. P-values for interaction and main effects for motor unit behavior at 30% MVIC 
pre- and post-supplementation. 
*Indicates significant interaction  
 
There was a significant Condition × Genotype interaction (F1,24 = 5.122; p = 
0.033; η2 = 0.176) for the A term in the MUAP vs. RT relationship. Follow-up 
independent samples t-tests indicated that the A term (collapsed across condition) was 
significantly greater in the SLOW versus FAST metabolizers (43.5 ± 21.1 mV vs. 29.0 ± 
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11.9 mV; p = 0.036) in the PLA condition. No other significant differences were 
observed (all p = 0.106-0.563).  
4.2.2.2 50% MVIC  
The p-values for the main and interaction effects from each of the ANOVAs for 
the relationships used to characterize MU behavior at 50% MVIC can be found below in 
Table 5. The average number of MUs analyzed per subject were: CAFPRE: 20.6 MUs 
(95% CI: 18.3-22.9 MUs), CAFPOST: 22.7 MUs (95% CI: 20.4-25.0 MUs), PLAPRE: 22.3 
MUs (95% CI: 20.4-24.2 MUs), and PLAPOST: 21.0 MUs (95% CI: 18.3-23.6 MUs). The 
mean RT range (% MVIC) for analyzed MUs were: CAFPRE: 10.8-41.6%, CAFPOST: 
12.6-42.0%, PLAPRE: 11.8-41.3%, and PLAPOST: 13.9-40.4%. Significant main and 
interaction effects are discussed below.  
 
 MFR vs. RT MUAP vs. RT MFR vs. MUAP 
 Slope Y-Int A b A b 
Condition 0.014† 0.022† 0.402 0.049† 0.335 0.498 
Condition x Genotype 0.196 0.646 0.366 0.870 0.229 0.427 
Time 0.065 0.022† 0.055 0.266 0.288 0.394 
Time x Genotype 0.691 0.657 0.567 0.998 0.383 0.467 
Condition x Time 0.622 0.648 0.069 0.019* 0.141 0.544 
Condition x Time x Genotype 0.566 0.908 0.322 0.838 0.434 0.338 
Genotype 0.211 0.645 0.086 0.739 0.057 0.317 
Table 5. P-values for interaction and main effects for motor unit behavior at 50% MVIC 
pre- and post-supplementation. 
†Indicates significant main effect  
*Indicates significant interaction 
 
There was a significant main effect for Condition (F1,24 = 7.007; p = 0.014; η
2 = 
0.226) for the slope of the MFR vs. RT relationship. Follow-up t-tests revealed that the 
slope was significantly lower (-0.51 ± 0.20 pps·RT-1 vs. -0.45 ± 0.17 pps·RT-1; p = 0.014) 
and that the y-intercept was significantly greater (27.5 ± 7.2 pps vs. 25.6 ± 5.8 pps; p = 
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0.022) in the PLA versus CAF condition. Additionally, there was a main effect for Time 
(F1,24 = 6.027; p = 0.022; η
2 = 0.201) the y-intercept of the MFR vs. RT relationship. Post-
hoc t-tests indicated that the y-intercept was significantly greater at POST than at PRE 
(27.7 ± 6.3 pps vs. 25.5 ± 5.5 pps; p = 0.018), when collapsed across conditions. Finally, 
a significant Condition x Time interaction (F1,24 = 6.344; p = 0.019; η
2 = 0.209) was 
observed for the MUAP vs. RT b term. Post hoc t-tests found significantly higher b term 
of the MUAP vs. RT relationship in the PLAPOST condition, when compared to CAFPOST 
(0.055 ± 0.017 mV vs. 0.046 ± 0.017 mV; p = 0.005). 
4.2.2.3 70% MVIC  
The p-values for the main and interaction effects from each of the ANOVAs for 
the relationships used to characterize MU behavior at 70% MVIC can be found below in 
Table 6. The average number of MUs analyzed per subject were: CAFPRE: 22.5 MUs 
(95% CI: 20.1-24.8 MUs), CAFPOST: 24.7 MUs (95% CI: 21.9-27.5 MUs), PLAPRE: 22.7 
MUs (95% CI: 20.1-25.3 MUs), and PLAPOST: 22.3 MUs (95% CI: 19.9-24.8 MUs). The 
mean RT range (% MVIC) for analyzed MUs were: CAFPRE: 21.3-58.9%, CAFPOST: 
21.0-55.5%, PLAPRE: 22.4-58.4%, and PLAPOST: 23.6-56.6%. No significant interaction 
or main effects were found for any relationship (all p = >0.05).  
 MFR vs. RT MUAP vs. RT MFR vs. MUAP 
 Slope Y-Int A b A b 
Condition 0.093 0.053 0.907 0.832 0.694 0.872 
Condition x Genotype 0.195 0.571 0.764 0.459 0.107 0.468 
Time 0.243 0.470 0.198 0.152 0.611 0.191 
Time x Genotype 0.613 0.350 0.721 0.636 0.704 0.472 
Condition x Time 0.210 0.268 0.463 0.535 0.321 0.875 
Condition x Time x Genotype 0.876 0.626 0.313 0.102 0.322 0.573 
Genotype 0.416 0.660 0.127 0.353 0.251 0.102 
Table 6. P-values for interaction and main effects for motor unit behavior at 70% MVIC 




Figure 2. A-C) Mean firing rate (MFR) vs. recruitment threshold (RT) relationships 
across contractions intensities at pre- (CAFPRE) and post-caffeine (CAFPOST), as well as 
pre- (PLAPRE) and post-placebo (PLAPOST). D-F) Motor unit action potential amplitude 
(MUAP) vs. RT relationships across contractions intensities at CAFPRE, CAFPOST, 
PLAPRE, and PLAPOST. G-I) MFR vs. MUAP relationships across contractions intensities 
at CAFPRE, CAFPOST, PLAPRE, and PLAPOST. 
 
4.2.3 Muscle Activation & Spinal Reflexes 
The p-values for the main and interaction effects from each of the ANOVAs for 
the relationships used to characterize muscle activation & spinal reflexes can be found 
below in Table 7. Significant main effects are discussed below.  
 %VA VLM VLRMS RFM SOLM SOLH 
Condition 0.653 0.354 0.692 0.514 0.725 0.265 
Condition x Genotype 0.998 0.747 0.936 0.866 0.652 0.571 
Time 0.792 0.131 0.726 0.146 0.067 0.068 
Time x Genotype 0.225 0.410 0.452 0.748 0.842 0.512 
Condition x Time 0.406 0.991 0.931 0.504 0.541 0.563 
Condition x Time x Genotype 0.234 0.139 0.107 0.053 0.117 0.762 
Genotype 0.003† 0.593 0.302 0.287 0.149 0.450 
Table 7. P-values for interaction and main effects for muscle activation and spinal 
excitability from pre- to post-supplementation. 




4.2.3.1 Voluntary Activation (%VA) 
There was a significant main effect for Genotype (F1,33 = 10.692; p = 0.003; η
2 = 
0.256) for %VA. Post-hoc analyses revealed a significantly greater %VA in the SLOW 
metabolizers when compared to FAST metabolizers (96.4 ± 3.0% vs. 93.9 ± 2.6%; p = 
0.003). No other significant interactions or main effects were found.  
4.2.3.2 Vastus Lateralis (VL) M-Wave (VLM)  
No significant interaction or main effects were found (p = >0.05).  
4.2.3.3 Normalized VL Electromyographic Amplitude (VLAMP)  
No significant interaction or main effects were found (p = >0.05).  
4.2.3.4 Rectus Femoris (RF) M-Wave (RFM)  
No significant interaction or main effects were found (p = >0.05).  
4.2.3.5 Normalized Soleus H-Reflex (SOLH)  
No significant interaction or main effects were found (p = >0.05).  
4.2.3.6 Soleus M-Wave (SOLM)  
No significant interaction or main effects were found (p = >0.05).  
4.2.4 Muscle Contractile Properties 
The p-values for the main and interaction effects from each of the ANOVAs for 
the relationships used to characterize muscle contractile properties can be found below in 
Tables 8-10. Due to difficulties with recording, only thirty-five subjects (FAST = 22; 
SLOW= 13) exhibited useable data at all time points (PRE, POST, and FATIGUE) for 
both conditions and were utilized in the final analyses. Significant main effects are 




 pTT +dt/dt  -dt/dt 
Condition 0.072 0.579 0.728 
Condition x Genotype 0.903 0.710 0.223 
Time 0.033† 0.007† 0.419 
Time x Genotype 0.339 0.157 0.445 
Condition x Time 0.384 0.576 0.507 
Condition x Time x Genotype 0.723 0.761 0.347 
Genotype 0.191 0.303 0.672 
Table 8. P-values for interaction and main effects for evoked singlet properties pre- and 
post-supplementation. 
†Indicates significant main effect 
 
4.2.4.1 Singlet Peak Twitch Torque (pTT)  
There was a significant main effect for Time (F1,33 = 4.927; p = 0.033; η
2 = 0.130) 
for pTT. Post-hoc paired samples t-tests found a significantly higher pTT at PRE when 
compared to POST (48.4 ± 11.1 Nm vs. 44.5 ± 12.4 Nm; p = 0.033), when collapsed 
across condition. No other significant interaction or main effects were found (p = >0.05). 
4.2.4.2 Singlet Peak Rate of Torque Development (+dt/dt) 
There was a significant main effect for Time (F1,33 = 8.318; p = 0.007; η
2 = 0.201) 
for +dt/dt. Post-hoc paired samples t-tests revealed a significantly greater +dt/dt at PRE 
when compared to POST (794.3 ± 298.3 Nm·s-1 vs. 700.9 ± 270.3 Nm·s-1; p = 0.007), 
when collapsed across condition. No other significant interaction or main effects were 
found (p = >0.05). 
4.2.4.3 Singlet Peak Relaxation Rate (-dt/dt) 






 pTTD +dt/dtD -dt/dtD 
Condition 0.003† 0.002† 0.017† 
Condition x Genotype 0.907 0.904 0.651 
Time <0.001† 0.025† 0.088 
Time x Genotype 0.655 0.718 0.945 
Condition x Time 0.864 0.357 0.029* 
Condition x Time x Genotype 0.651 0.027* 0.143 
Genotype 0.253 0.612 0.117 
Table 9. P-values for interaction and main effects for evoked resting doublet properties 
pre- and post-supplementation. 
*Indicates significant interaction effect  
†Indicates significant main effect 
 
4.2.4.4 Resting Doublet Peak Twitch Torque (pTTD) 
There was a significant main effect for Condition (F1,33 = 10.560; p = 0.003; η
2 = 
0.242) for pTTD. Post-hoc paired samples t-tests found a significant greater during CAF 
when compared to PLA (53.4 ± 12.3 Nm vs. 49.7 ± 13.0; p = 0.003), when collapsed 
across time. There was also a significant main effect for Time (F1,33 = 16.362; p = 
<0.001; η2 = 0.331) for PTTD. Paired samples t-tests found that PRE was significantly 
greater than POST (54.8 ± 12.5 Nm vs. 48.3 ± 13.5 Nm; p = <0.001), when collapsed 
across condition. No other significant interaction or main effects were found (p = >0.05). 
4.2.4.5 Resting Doublet Peak Rate of Torque Development (+dt/dtD) 
There was a significant Condition x Time x Genotype interaction (F1,33 = 95.345; 
p = 0.027; η2 = 0.139) for +dt/dtPOT. Post-hoc paired samples t-tests found a significantly 
greater +dt/dtPOT in FAST during the CAFPRE condition when compared to PLAPOST 
(1040.5 ± 217.5 Nm·s-1 vs. 896.9 ± 209.7 Nm·s-1; p = <0.001). No other significant 





4.2.4.6 Resting Doublet Peak Relaxation Rate (-dt/dtD)  
There was a significant Condition x Time interaction (F1,33 = 5.196; p = 0.029; η
2 
= 0.136) for -dt/dtD. Post-hoc paired samples t-tests found that PLAPOST had significantly 
slower -dt/dtD than all other conditions (p = 0.002-0.011). No other significant interaction 
or main effects were found (p = >0.05).    
 pTTPOT  +dt/dtPOT -dt/dtPOT 
Condition 0.013† 0.013† 0.004† 
Condition x Genotype 0.446 0.776 0.406 
Time <0.001† 0.002† 0.036† 
Time x Genotype 0.843 0.775 0.447 
Condition x Time 0.825 0.854 0.393 
Condition x Time x Genotype 0.206 0.103 0.427 
Genotype 0.270 0.637 0.252 
Table 10. P-values for interaction and main effects for evoked potentiated doublet 
properties pre- and post-supplementation. 
*Indicates significant interaction effect  
†Indicates significant main effect 
 
4.2.4.7 Potentiated Doublet Peak Twitch Torque (pTTPOT)  
There was a significant main effect for Condition (F1,33 = 6.963; p = 0.013; η
2 = 
0.174) for pTTPOT. Post-hoc paired samples t-tests found a significantly greater pTTPOT 
during CAF when compared to PLA (69.1 ± 14.7 Nm vs. 64.6 ± 15.8; p = 0.013), when 
collapsed across time. There was also a main effect for Time (F1,33 = 23.138; p = <0.001; 
η2 = 0.412) for pTTPOT. Post-hoc paired samples t-tests found that PRE was significantly 
greater than POST (71.5 ± 14.3 Nm vs. 62.1 ± 16.8 Nm; p = <0.001), when collapsed 
across condition. No other significant interaction or main effects were found (p = >0.05). 
4.2.4.8 Potentiated Doublet Peak Rate of Torque Development (+dt/dtPOT) 
There was a significant main effect for Condition (F1,33 = 6.844; p = 0.013; η
2 = 
0.172) for +dt/dtPOT. Post-hoc paired samples t-tests found significantly greater +dt/dtPOT 
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values during the CAF condition when compared to PLA (1305.0 ± 255.8 Nm·s-1 vs. 
1217.9 ± 282.4 Nm·s-1; p = 0.013), when collapsed across time. There was also a 
significant main effect for Time (F1,33 = 11.581; p = 0.002; η
2 = 0.260) for +dt/dtPOT. 
Post-hoc paired samples t-tests found significantly greater +dt/dtPOT values at PRE when 
compared to POST (1318.1 ± 262.7 Nm·s-1 vs. 1204.9 ± 279.1 Nm·s-1; p = 0.002), when 
collapsed across conditions. No other significant interaction or main effects were found 
(p = >0.05).  
4.2.4.9 Potentiated Doublet Peak Relaxation Rate (-dt/dtPOT)  
There was a significant main effect for Condition (F1,33 = 9.364; p = 0.004; η
2 = 
0.221) for -dt/dtPOT. Post-hoc paired samples t-tests found a significantly faster -dt/dtPOT 
during CAF when compared to PLA (-701.1 ± 191.8 Nm·s-1 vs. -631.3 ± 178.2 Nm·s-1; p 
= 0.005), when collapsed across time. There was also a significant main effect for Time 
(F1,33 = 4.798; p = 0.036; η
2 = 0.127) for -dt/dtPOT. Post-hoc paired samples t-tests 
revealed a significantly faster -dt/dtPOT at PRE when compared to (-691.7 ± 187.1 Nm·s
-1 
vs. -640.7 ± 191.7 Nm·s-1; p = 0.005), when collapsed across conditions. No other 
significant interaction or main effects were found (p = >0.05).  
4.3 Neuromuscular Function & Fatigue   
4.3.1 MU Behavior 
The following results represent data examining the relationship between MFR, 
RT, and MUAP amplitude during the first (FIRST), middle (MID), and last (LAST) 
repetition during the fatigue protocol of both the CAF and PLA conditions. The p-values 
for the main and interaction effects from each of the ANOVAs for the relationships used 
to characterize MU behavior during fatigue can be found below in Table 11. The average 
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number of MUs analyzed per subject were: CAFFIRST: 21.8 MUs (95% CI: 19.1-24.5 
MUs), CAFMID: 21.0 MUs (95% CI: 18.2-23.8 MUs), CAFLAST: 19.4 MUs (95% CI: 
16.6-22.2 MUs), PLAFIRST: 21.3 MUs (95% CI: 18.9-23.6 MUs), PLAMID: 19.5 MUs 
(95% CI: 17.1-21.9 MUs), and PLALAST: 18.8 MUs (95% CI: 16.3-21.2 MUs). The mean 
RT range (% MVIC) for analyzed MUs were: CAFFIRST: 14.9-38.4%, CAFMID: 15.0-
39.7%, CAFLAST: 17.5-42.3%, PLAFIRST: 15.1-39.3%, PLAMID: 18.6-43.3%, and 
PLALAST: 18.1-41.5%. Significant main and interaction effects are discussed below.  
 MFR vs. RT MUAP vs. RT MFR vs. MUAP 
 Slope Y-Int A b A b 
Condition 0.794 0.870 0.861 0.253 0.381 0.186 
Condition x Genotype 0.283 0.203 0.102 0.102 0.691 0.808 
Time 0.480 0.748 <0.001* <0.001* 0.101 0.711 
Time x Genotype 0.987 0.627 0.132 0.821 0.758 0.457 
Condition x Time 0.620 0.977 0.468 0.122 0.139 0.204 
Condition x Time x Genotype 0.977 0.867 0.560 0.641 0.345 0.590 
Genotype 0.314 0.227 0.797 0.535 0.370 0.722 
Table 11. P-values for interaction and main effects for motor unit behavior during 
fatigue. 
*Indicates significant main effect  
 
4.3.1.1 RT vs. MFR slope 
No significant interaction or main effects were found (p = >0.05).  
4.3.1.2 RT vs. MFR y-intercept 
No significant interaction or main effects were found (p = >0.05).  
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Figure 3. Mean firing rate (MFR) vs. recruitment threshold (RT) relationship during the 
fatigue protocol during both the caffeine (CAF) and placebo (PLA) conditions.  
 
4.3.1.3 RT vs. MUAP A Term 
There was a significant main effect for Time (F1.4,35.1 = 16.388; p = <0.001; η
2 = 
0.396) in the RT vs. MUAP A term during fatigue. Post-hoc paired samples t-tests 
revealed a significantly lower RT vs. MUAP A term during FIRST when compared to 
MID (34.8 ± 27.9 mV vs. 46.1 ± 25.5 mV; p = <0.001), during FIRST when compared to 
LAST (34.8 ± 27.9 mV vs. 58.1 ± 38.4 mV; p = <0.001) and MID when compared to 
LAST (46.1 ± 25.5 mV vs. 58.1 ± 38.4 mV; p = <0.001), when collapsed across 
condition. No other significant interaction or main effects were found (p = >0.05).  
4.3.1.4 RT vs. MUAP b Term 
There was a significant main effect for Time (F2,50 = 9.803; p = <0.001; η
2 = 
0.282) in the RT vs. MUAP b term during fatigue. Post-hoc paired samples t-tests 
revealed a significantly greater RT vs. MUAP b term during FIRST when compared to 
MID (0.058 ± 0.022 mV/%MVIC vs. 0.046 ± 0.019 mV/%MVIC; p = 0.001) and during 
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FIRST when compared to LAST (0.058 ± 0.022 mV/%MVIC vs. 0.044 ± 0.019 mV/%MVIC; 
p = 0.003), when collapsed across conditions. No other significant interaction or main 
effects were found (p =0 >0.05).  
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Figure 4. Motor unit action potential amplitude (MUAP) vs. recruitment threshold (RT) 
relationship during the fatigue protocol during both the caffeine (CAF) and placebo 
(PLA) conditions. Significant main effects are discussed above in section 4.1.3.3 and 
4.1.3.4.  
 
4.3.1.5 MUAP vs. MFR A term 
No significant interaction or main effects were found (p = >0.05).  
4.3.1.6 MUAP vs. MFR b term  
No significant interaction or main effects were found (p = >0.05).  
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Figure 5. Mean firing rate (MFR) vs. motor unit action potential amplitude (MUAP) 
relationship during the fatigue protocol during both the caffeine (CAF) and placebo 
(PLA) conditions.  
 
4.3.2 Muscle Activation 
4.3.2.1 %VA  
There was a significant main effect for Time (F1,33 = 9.016; p = 0.005; η
2 = 0.231) 
for Voluntary Activation. Post-hoc paired samples t-tests revealed a significantly lower 
VA post-fatigue (89.9 ± 7.5% vs. 94.8 ± 3.8%; p = 0.005) when collapsed across 
conditions. No other interaction or main effects were found (p = >0.05).   
4.3.3 Muscle Contractile Properties 
 The p-values for the main and interaction effects from each of the ANOVAs for 
the relationships used to characterize muscle contractile properties can be found below in 




 pTTD +dt/dtD -dt/dtD 
Condition 0.226 0.137 0.008† 
Condition x Genotype 0.788 0.349 0.378 
Time <0.001† <0.001† <0.001† 
Time x Genotype 0.176 0.361 0.069 
Condition x Time 0.029* 0.010* 0.014* 
Condition x Time x Genotype 0.915 0.598 0.580 
Genotype 0.132 0.873 0.399 
Table 12. P-values for interaction and main effects for evoked resting doublet properties 
pre- and post-fatigue. 
*Indicates significant interaction effect  




There was a significant Condition x Time (F1,33 = 5.208; p = 0.029; η
2 = 0.136) for 
pTTD. Post-hoc paired samples t-tests revealed pTTD was significantly greater at 
CAFPOST when compared to PLAPOST (50.1 ± 14.2 Nm vs. 46.5 ± 13.9 Nm; p = 0.007), 
CAFFATIGUE (50.1 ± 14.2 Nm vs. 20.2 ± 11.4 Nm; p = <0.001) and PLAFATIGUE (50.1 ± 
14.2 Nm vs. 21.4 ± 12.3 Nm; p = <0.001). Analyses also revealed significantly higher 
pTTD at PLAPOST than CAFFATIGUE (46.5 ± 13.9 Nm vs. 20.2 ± 11.4 Nm; p = <0.001) and 
PLAFATIGUE (46.5 ± 13.9 Nm vs. 21.4 ± 12.3 Nm; p = <0.001). No other significant 




Figure 6. Individual subject plots for resting doublet peak twitch torque (pTTD) prior to- 
and post-fatigue in the caffeine (CAF) and placebo (PLA) conditions. The orange bars 
represent the groups mean at that time point.  
*Indicates significantly greater pTTD at CAFPOST when compared to CAFFATIGUE 
# Indicates significantly greater pTTD at PLAPOST when compared to PLAFATIGUE 




There was a significant Condition x Time (F1,33 = 7.534; p = 0.010; η
2 = 0.186) for 
+dt/dtD. Post-hoc paired samples t-tests revealed +dt/dtD was significantly greater at 
CAFPOST when compared to PLAPOST (955.0 ± 234.6 Nm·s
-1 vs. 875.4 ± 234.1 Nm·s-1; p 
= 0.004), CAFFATIGUE (955.0 ± 234.6 Nm·s
-1 vs. 426.0 ± 214.5 Nm; p = <0.001) and 
PLAFATIGUE (955.0 ± 234.6 Nm·s
-1 vs. 445.9 ± 234.8 Nm·s-1; p = <0.001). Analyses also 
revealed significantly higher +dt/dtD at PLAPOST than CAFFATIGUE (875.4 ± 234.1 Nm·s
-1 
vs. 426.0 ± 214.5 Nm·s-1; p = <0.001) and PLAFATIGUE (875.4 ± 234.1 Nm·s
-1 vs. 445.9 ± 
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234.8 Nm·s-1; p = <0.001). No other significant interaction or main effects were found (p 
= >0.05).  
 
Figure 7. Individual subject plots for resting doublet peak rate of twitch torque 
development (+dt/dtD) prior to- and post-fatigue in the caffeine (CAF) and placebo (PLA) 
conditions. The orange bars represent the groups mean at that time point.  
*Indicates significantly greater +dt/dtD at CAFPOST when compared to CAFFATIGUE 
# Indicates significantly greater +dt/dtD at PLAPOST when compared to PLAFATIGUE 
† Indicates significantly greater +dt/dtD at CAFPOST when compared to PLAPOST 
 
 
4.3.3.3 -dt/dtD   
There was a significant Condition x Time (F1,33 = 6.729; p = 0.014; η
2 = 0.169) for 
-dt/dtD. Post-hoc paired samples t-tests indicated significantly faster -dt/dtD during 
CAFPOST when compared to PLAPOST (-447.5 ± 134.5 Nm·s
-1 vs. -389.5 ± 119.0 Nm·s-1), 
CAFFATIGUE (-447.5 ± 134.5 Nm·s
-1 vs. -173.9 ± 83.3 Nm·s-1), and PLAFATIGUE (-447.5 ± 
134.5 Nm·s-1 vs. -167.8 ± 86.9 Nm·s-1). Analyses also revealed significantly faster -dt/dtD 
at PLAPOST when compared to CAFFATIGUE (-389.5 ± 119.0 Nm·s
-1 vs. -173.9 ± 83.3 
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Nm·s-1) and PLAFATIGUE (-389.5 ± 119.0 Nm·s
-1 vs. -167.8 ± 86.9 Nm·s-1). No other 
significant interaction or main effects were found (p = >0.05).  
 
Figure 8. Individual subject plots for resting doublet peak rate of relaxation(-dt/dtD) prior 
to- and post-fatigue in the caffeine (CAF) and placebo (PLA) conditions. The orange bars 
represent the groups mean at that time point.  
*Indicates significantly faster -dt/dtD at CAFPOST when compared to CAFFATIGUE 
# Indicates significantly faster -dt/dtD at PLAPOST when compared to PLAFATIGUE 
† Indicates significantly faster -dt/dtD at CAFPOST when compared to PLAPOST 
 
 pTTPOT  +dt/dtPOT -dt/dtPOT 
Condition 0.223 0.170 0.013† 
Condition x Genotype 0.672 0.420 0.973 
Time <0.001† <0.001† <0.001† 
Time x Genotype 0.202 0.376 0.142 
Condition x Time 0.026* 0.019* 0.010* 
Condition x Time x Genotype 0.818 0.788 0.694 
Genotype 0.561 0.909 0.316 
Table 13. P-values for interaction and main effects for evoked potentiated doublet 
properties pre- and post-fatigue. 
*Indicates significant interaction effect  





There was a significant Condition x Time (F1,33 = 5.436; p = 0.026; η
2 = 0.141) for 
pTTPOT. Post-hoc paired samples t-tests revealed pTTPOT was significantly greater at 
CAFPOST when compared to CAFFATIGUE (64.1 ± 17.2 Nm vs. 23.3 ± 12.4 Nm; p = 
<0.001) and PLAFATIGUE (64.1 ± 17.2 Nm vs. 24.3 ± 12.8 Nm; p = <0.001). Analyses also 
revealed significantly higher pTTPOT at PLAPOST than CAFFATIGUE (60.2 ± 17.6 Nm vs. 
23.3 ± 12.4 Nm; p = <0.001) and PLAFATIGUE (60.2± 17.6 Nm vs. 24.3 ± 12.8 Nm; p = 
<0.001). No other significant interaction or main effects were found (p = >0.05).    
4.3.3.5 +dt/dtPOT  
There was a significant Condition x Time (F1,33 = 6.033; p = 0.019; η
2 = 0.155) for 
+dt/dtPOT. Post-hoc paired samples t-tests revealed +dt/dtPOT was significantly greater at 
CAFPOST when compared to CAFFATIGUE (1245.7 ± 268.6 Nm·s
-1 vs. 493.9 ± 235.9 Nm·s-
1; p = <0.001) and PLAFATIGUE (1245.7 ± 268.6 Nm·s
-1 vs. 506.9 ± 252.9 Nm·s-1; p = 
<0.001). Analyses also revealed significantly higher +dt/dtPOT at PLAPOST than 
CAFFATIGUE (1164.1 ± 318.2 Nm·s
-1 vs. 493.9 ± 235.9 Nm·s-1; p = <0.001) and 
PLAFATIGUE (1164.1 ± 318.2 Nm·s
-1 vs. 506.9 ± 252.9 Nm·s-1; p = <0.001). No other 
significant interaction or main effects were found (p = >0.05).  
4.3.3.6 -dt/dtPOT   
There was a significant Condition x Time (F1,33 = 7.496; p = 0.010; η
2 = 0.185) for 
-dt/dtPOT. Post-hoc paired samples t-tests indicated significantly faster -dt/dtPOT during 
CAFPOST when compared to PLAPOST (-680.6 ± 215.4 Nm·s
-1 vs. -600.7 ± 191.5 Nm·s-1), 
CAFFATIGUE (-680.6 ± 215.4 Nm·s
-1 vs. -197.3 ± 105.4 Nm·s-1), and PLAFATIGUE (-680.6 ± 
215.4 Nm·s-1 vs. -190.8 ± 98.4 Nm·s-1). Analyses also revealed significantly faster -
66 
 
dt/dtPOT at PLAPOST when compared to CAFFATIGUE (-600.7 ± 191.5 Nm·s
-1 vs. -197.3 ± 
105.4 Nm·s-1) and PLAFATIGUE (-600.7 ± 191.5 Nm·s
-1 vs. -190.8 ± 98.4 Nm·s-1). No 
other significant interaction or main effects were found (p = >0.05). 
 
Figure 9. A/B) Relationship between % Change in MVIC and % Change in peak resting 
doublet twitch torque (pTTD) from pre- to 1-hour post-supplementation in the caffeine 
and placebo conditions, respectively. C/D) Relationship between % Change in MVIC and 
% Change in peak resting doublet peak relaxation rate (-dT/dtD) from pre- to 1-hour post-
supplementation in the caffeine and placebo conditions, respectively. 
 
4.4 Time-Course of Fatigue  
4.4.1 Average Torque (TQAVG)  
There was a significant main effect for Condition (F1,26 = 8.645; p = 0.007; η
2 = 
0.250) for TQAVG. Post-hoc paired samples t-tests indicated a significantly greater TQAVG 
during CAF when compared to PLA (140.1 ± 36.0 Nm vs. 131.7 ± 38.7 Nm; p = 0.007), 
when collapsed across time. There was also a significant main effect for Time (F2,52 = 
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6.585; p = 0.003; η2 = 0.202) for TQAVG. Follow-up paired samples t-tests found a 
significantly higher TQAVG at FIRST versus LAST (136.5 ± 36.7 Nm vs. 135.0 ± 36.6 
Nm; p = 0.010), when collapsed across condition. No other significant interaction or main 
effects were found (P = >0.05).  
4.4.2 Torque SD (TQSD)  
There was a significant Condition x Time interaction (F1.3,34.7 = 3.644; p = 0.033; 
η2 = 0.123) for TQSD. Follow-up paired samples t-tests revealed significantly lower TQSD 
values during CAFFIRST when compared to CAFLAST (3.4 ± 1.2 Nm vs. 4.8 ± 1.7 Nm; p = 
0.001) and during CAFMID when compared to CAFLAST (3.3 ± 0.9 Nm vs. 4.8 ± 1.7 Nm; p 
= <0.001). Follow-up analyses also revealed a significantly lower TQSD during PLAFIRST 
when compared to PLALAST (3.1 ± 1.0 Nm vs. 5.6 ± 2.2 Nm; p = <0.001) and during 
PLAMID when compared to PLALAST (3.6 ± 1.3 Nm vs. 5.6 ± 2.2 Nm; p = <0.001). 
Analyses also found significantly lower TQSD during CAFFIRST when compared to 
PLALAST (3.4 ± 1.2 Nm vs. 5.6 ± 2.2 Nm; p = <0.001), CAFMID when compared to 
PLALAST (3.3 ± 0.9 Nm vs. 5.6 ± 2.2 Nm; p = <0.001), and PLAFIRST when compared to 
CAFLAST (3.1 ± 1.0 Nm vs. 4.8 ± 1.7 Nm; p = <0.001), and PLAMID when compared to 
CAFLAST (3.6 ± 1.3 Nm vs. 4.8 ± 1.7 Nm; p = 0.001). No other significant interaction or 
main effects were found (p = >0.05).   
4.4.3 CV Torque (TQCV)  
There was a significant Condition x Time interaction (F1.3,34.4 = 3.818; p = 0.048; 
η2 = 0.128) for TQCV. Follow-up paired samples t-tests found a significantly lower TQCV 
at CAFFIRST when compared to CAFLAST (2.5 ± 0.8% vs. 3.7 ± 1.8%; p = 0.001) and at 
CAFMID when compared to CAFLAST (2.4 ± 0.7% vs. 3.7 ± 1.8%; p = <0.001). 
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Significantly lower TQCV values were found during CAFFIRST when compared to 
PLALAST (2.5 ± 0.8% vs. 4.5 ± 1.8%; p = <0.001), CAFMID when compared to PLALAST 
(2.4 ± 0.7% vs. 4.5 ± 1.8%; p = <0.001), PLAFIRST when compared to PLALAST (2.5 ± 
0.9% vs. 4.5 ± 1.8%; p = <0.001) and PLAFIRST when compared to CAFLAST (2.5 ± 0.9% 
vs. 3.7 ± 1.8%; p = 0.001). No other interaction or main effects were found (p = >0.05).  
 
Figure 10. Visual representative of the mean torque coefficient of variation (TQCV) ± SD 
at the first, middle, and last repetition of the fatigue protocols in the caffeine (CAF) and 
placebo (PLA) conditions.  
†Indicates significantly lower TQCV at CAFFIRST when compared to CAFLAST 
*Indicates significantly lower TQCV at CAFMID when compared to CAFLAST 
#Indicates significantly lower TQCV at PLAFIRST when compared to PLALAST 
 
4.4.4 TQ Impulse (TQIMP)  
There was a significant Condition x Time interaction (F2,52 = 5.501; p = 0.010; η
2 
= 0.163) for TQIMP. Follow-up paired samples t-tests found a significantly greater TQIMP 
at CAFFIRST when compared to PLALAST (2086.6 ± 547.0 Nm·s vs. 1913.6 ± 569.4 Nm·s; 
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p = 0.001), CAFMID when compared to PLALAST (2069.0 ± 525.5 Nm·s vs. 1913.4 ± 
569.4 Nm·s; p = 0.003) and PLAFIRST when compared to PLALAST (1985.0 ± 584.6 Nm·s 
vs. 1913.6 ± 569.4 Nm·s; p = 0.002). No other significant interaction or main effects 
were found (p = >0.05).  
 
Figure 11. Visual representative of the mean torque impulse (TQIMP) ± SD at the first, 
middle, and last repetition of the fatigue protocols in the caffeine (CAF) and placebo 
(PLA) conditions.  
*Indicates significantly greater TQIMP at PLAFIRST when compared to PLALAST 
 
4.4.5 VL Integrated EMG (VLiEMG) 
There was a significant main effect for Time (F1.1,27.7 = 57.72; p = <0.001; η
2 = 
0.689) for VLiEMG. Post-hoc paired samples t-tests indicated that VLiEMG was significantly 
lower at FIRST when compared to MID (1.44 ± 0.58 µV vs. MID: 1.74 ± 0.68 µV; p = 
<0.001), at FIRST when compared to LAST (1.44 ± 0.58 µV vs. 2.11 ± 0.90 µV; p = 
<0.001), and at MID when compared to LAST (1.74 ± 0.68 µV vs. 2.11 ± 0.90 µV; p = 
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<0.001), when collapsed across condition. No other significant interaction or main effects 
were found (p = >0.05). 
 
Figure 12. Visual representative of the mean vastus lateralis integrated 
electromyography (VLiEMG) ± SD at the first, middle, and last repetition of the fatigue 
protocols in the caffeine (CAF) and placebo (PLA) conditions.  
*Indicates significantly lower VLiEMG at FIRST when compared to MID, when collapsed 
across condition. 
†Indicates significantly lower VLiEMG at MID when compared to LAST, when collapsed 
across condition. 
#Indicates significantly lower VLiEMG at FIRST when compared to LAST, when 
collapsed across condition. 
 
4.4.6 VL Median Power Frequency (VLMDF)  
There was a significant main effect for Time (F1.2,31.7 = 41.936; p = <0.001; η
2 = 
0.617) for VLMDF. Post-hoc paired samples t-tests found significantly higher VLMDF 
values at FIRST when compared to MID (80.5 ± 17.5 Hz vs. 76.6 ± 16.4 Hz; p = <0.001), 
at FIRST when compared to LAST (80.5 ± 17.5 Hz vs. 69.8 ± 16.8 Hz; p = <0.001), and 
at MID when compared to LAST (76.6 ± 16.4 Hz vs. 69.8 ± 16.8 Hz; p = <0.001), when 
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collapsed across condition. No other significant interaction or main effects were found (p 
= >0.05).  
 
Figure 13. Visual representative of the mean vastus lateralis median power frequency 
(VLMDF) ± SD at the first, middle, and last repetition of the fatigue protocols in the 
caffeine (CAF) and placebo (PLA) conditions.  
*Indicates significantly greater VLMDF at FIRST when compared to MID, when collapsed 
across condition.  
†Indicates significantly greater VLMDF at MID when compared to LAST, when collapsed 
across condition. 
#Indicates significantly greater VLMDF at FIRST when compared to LAST, when 
collapsed across condition. 
 
4.4.7 VLAMP  
There was a significant main effect for Condition (F1,26 = 4.754; p = 0.038; η
2 = 
0.155) for VLAMP. Post-hoc paired samples t-tests found significantly higher VLAMP 
during CAF when compared PLA (0.074 ± 0.053 µVs-1 vs. 0.051 ± 0.032 µVs-1; p = 
0.038), when collapsed across time. There was also a significant main effect for Time 
(F1.0,27.2 = 48.237; p = <0.001; η
2 = 0.650) for VLAMP. Follow-up paired samples t-test 
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found that VLAMP was significantly lower at FIRST when compared to MID (0.050  ± 
0.036 µVs-1 vs. 0.062 ± 0.044 µVs-1; p = <0.001), FIRST when compared to LAST 
(0.050 ± 0.036 µVs-1 vs. 0.076 ± 0.055 µVs-1; p = <0.001), and MID when compared to 
LAST (0.062 ± 0.044 µVs-1 vs. 0.076 ± 0.055 µVs-1; p = <0.001), when collapsed across 
time. No other significant interaction or main effects were found (p = >0.05).  
4.4.8 RF iEMG (RFiEMG)  
There was a significant main effect for Time (F1.1,28.1 = 41.478; p = <0.001; η
2 = 
0.615) for RFiEMG. Post-hoc paired samples t-tests indicated significantly lower RFiEMG 
values at FIRST when compared to MID (1.26 ± 0.63 µV vs. 1.54 ± 0.74 µV; p = 
<0.001), FIRST when compared to LAST (1.26 ± 0.63 µV vs. 1.88 ± 0.99 µV; p = 
<0.001), and MID when compared to LAST (1.54 ± 0.74 µV vs. 1.88 ± 0.99 µV; p 
<0.001), when collapsed across condition. No other significant interaction or main effects 
were found (p = >0.05).   
 
Figure 14. Visual representative of the mean rectus femoris integrated electromyography 
(RFiEMG) ± SD at the first, middle, and last repetition of the fatigue protocols in the 
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caffeine (CAF) and placebo (PLA) conditions.  
*Indicates significantly lower RFiEMG at FIRST when compared to MID, when collapsed 
across condition. 
†Indicates significantly lower RFiEMG at MID when compared to LAST, when collapsed 
across condition. 
#Indicates significantly lower RFiEMG at FIRST when compared to LAST, when collapsed 
across condition. 
 
4.4.9 RF MDF (RFMDF)  
There was a significant main effect for Time (F1.2,32.1 = 29.139; p = <0.001; η
2 = 
0.528) for RFMPF. Follow-up paired samples t-tests indicated significantly greater RFMPF 
at FIRST when compared to MID (76.7 ± 15.7 Hz vs. 72.8 ± 13.6 Hz; p = 0.002), FIRST 
when compared to LAST (76.7 ± 15.3 Hz vs. 66.1 ± 14.3 Hz; p = <0.001), and MID 
when compared to LAST (72.8 ± 13.6 Hz vs. 66.1 ± 14.3 Hz; p = <0.001), when 





Figure 15. Visual representative of the mean rectus femoris median power frequency 
(RFMDF) ± SD at the first, middle, and last repetition of the fatigue protocols in the 
caffeine (CAF) and placebo (PLA) conditions.  
*Indicates significantly greater RFMDF at FIRST when compared to MID, when collapsed 
across condition.  
†Indicates significantly greater RFMDF at MID when compared to LAST, when collapsed 
across condition. 
#Indicates significantly greater RFMDF at FIRST when compared to LAST, when 
collapsed across condition. 
 
4.4.10 Normalized RF EMG AMP (RFAMP)  
There was a significant main effect for Time (F1.1,28.4 = 36.946; p = <0.001; η
2 = 0.587) 
for RFAMP. Post-hoc paired samples t-tests indicated significantly lower RFAMP values at 
FIRST when compared to MID (0.041 ± 0.028 µVs-1 vs. 0.051 ± 0.034 µVs-1; p = 
<0.001), FIRST when compared to LAST (0.041 ± 0.028 µVs-1 vs. 0.062 ± 0.045 µVs-1; 
p = <0.001), and MID when compared to LAST (0.051 ± 0.035 vs. 0.062 ± 0.045; p = 
<0.001), when collapsed across condition. No other significant interaction or main effects 







The purpose of this investigation was to examine whether genetic variation in 
CYP1A2 (-163A>C, rs762551) influences the effects of acute caffeine supplementation 
on neuromuscular function of the lower body at rest and in response to a fatiguing work 
bout. The main finding from this investigation was an overall lack of ergogenic effects of 
caffeine on neuromuscular function of the lower body musculature. However, the present 
data suggest that caffeine may augment the decline seen following rest in the placebo 
condition. These findings are fully discussed below at rest (section 5.1) and immediately 
following fatigue (section 5.2). 
5.1 Neuromuscular Function: Pre vs. Post Supplementation   
 
Caffeine has been widely studied for its proposed ergogenic effects, especially prior 
to exercise. While several proposed mechanisms exist, caffeine’s primary mechanism of 
action is thought to be through adenosine receptor antagonism. As adenosine receptors 
are located in a variety of tissues throughout the human body (Reppert et al. 1991), it has 
been hypothesized that caffeine may impact skeletal muscle through peripheral, spinal, 
and/or supraspinal mechanisms (Fimland et al. 2010; Kalmar 2005). Therefore, a variety 
of measurements were employed in the present investigation to elucidate the potential 
physiological mechanisms associated with caffeine supplementation. 
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In terms of exercise, caffeine is commonly used as an ergogenic aid and has been 
purported to increase muscular function, especially prior to resistance exercise (see 
review by (Grgic et al. 2018). However, to date, much of the data has been conflicting, 
especially in terms of muscular strength. For example, several investigations have 
reported no change in maximal strength (Behrens et al. 2015b; Fimland et al. 2010) 
following caffeine supplementation, with one investigator even reporting a decrease in 
maximal strength (Bond et al. 1986). On the contrary, a meta-analysis by Warren et al. 
(2010) reported a moderate effect (ES = 0.19) for maximal strength, which equated to 
roughly a 4% improvement over placebo. Interestingly, the authors performed a separate 
muscle-specific analysis, which indicated that caffeine may have a more potent effect on 
maximal strength in the quadriceps musculature (ES = 0.37), with an estimated 7% 
increase in maximal strength when compared to placebo (Warren et al. 2010). However, 
in the present investigation, we failed to show a significant improvement in quadriceps 
MVIC strength following caffeine administration. Caffeine did, however, offset the 
decline in MVIC seen in the placebo condition (Figure 1). While the present data exhibits 
“responders” and “non-responders” similar to the previous work of Meyers and Cafarelli 
(2005), the vast majority of subjects in the present study would be classified as non-
responders to caffeine supplementation, as 24 out of 35 subjects analyzed had a decreased 
MVT following from CAFPRE to CAFPOST . Thus, caffeine may have a potential utility in 
maintaining muscle function in settings of prolonged rest, such as prolonged traveling to 
events, reserve athletes in sporting events, etc. However, taken as a whole, the results of 
the present investigation do not support the efficacy of caffeine administration for 
improved muscular strength, contrary to much of the previous literature. 
77 
 
A large portion of the previous literature has suggested that augmented CNS 
activity is the most plausible explanation for the ergogenic effects reported by previous 
authors (Behrens et al. 2015a; Meyers and Cafarelli 2005; Plaskett and Cafarelli 2001; 
Tarnopolsky and Cupido 2000). More specifically, a number of authors have suggested 
this may be due to an increase in MU recruitment and/or increased MU firing rates 
(Bazzucchi et al. 2011; Kalmar et al. 2006). As the MU is the final pathway of the central 
nervous system and directly integrates with skeletal muscle, it is logical to hypothesize 
the improvements in skeletal muscle function may be facilitated through augmented MU 
behavior. However, our results indicate an overall lack of change in MU firing behavior 
following caffeine administration, when compared to pre-supplement or placebo 
conditions. Although the previous work of Walton and colleagues (2002) found a 
significant increase in self-sustaining firing rates of MUs in the tibialis anterior following 
caffeine ingestion, our results align with those of Meyers and Cafarelli (2005) and 
Kalmar and Cafarelli (1999), who reported no alteration in MU firing behavior following 
caffeine supplementation. Interestingly, each of these previous investigations used the 
same caffeine dosage as the present investigation (i.e. 6 mg/kg/bw). It is worth noting the 
potential for muscle specific alterations in MU behavior, as Walton et al. (2002) 
examined the tibialis anterior, while our work and that of Kalmar and Cafarelli (1999) 
and Meyers and Cafarelli (2005) examined MU behavior of the quadriceps musculature. 
However, it is premature to draw any specific conclusion until more data is available. 
Finally, it is important to acknowledge that in the present investigation, MVT was greater 
at CAFPOST compared to PLAPOST. Therefore, it appears there may be a reduced 
neuromuscular efficiency following PLA, as the same level of excitation to the 
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motorneuron pool, as evidenced by no significant changes in global EMG or MU firing 
properties, was required for a lower absolute force output.  
Since its appearance in the literature by Merton (1954), the interpolated twitch 
technique (ITT) has become a common tool to assess muscle activation, or in simpler 
terms, the percentage of muscle subjects are able to voluntary activate (%VA; (Behm et 
al. 1996). Previous research has reported conflicting results, with several authors (Kalmar 
and Cafarelli 2004; Meyers and Cafarelli 2005; Tarnopolsky and Cupido 2000) reporting 
no change in %VA, and others reporting significant increases (Behrens et al. 2015a; 
Kalmar and Cafarelli 1999; Plaskett and Cafarelli 2001), including a meta-analysis by 
Warren et al. (2010) reporting a large (ES = 0.67) effect for caffeine on quadriceps %VA. 
However, similar to the previously discussed MVIC data, we failed to see any significant 
changes in %VA following either CAF or PLA in the present investigation. While not all 
of the subjects in the present investigation were resistance-trained, the population was at 
least recreationally active and exhibited a high degree of %VA at baseline (95.0 ± 4.0% 
when collapsed across genotype; (Herda et al. 2011). Thus, the potential for an increase 
in %VA following caffeine administration may have been limited. Thus, we failed to 
reported any increases in excitation following caffeine supplementation. Our data also 
indicate that there was no increase in spinal excitability following caffeine. Traditionally 
used as a surrogate for spinal excitability, the H-Reflex reflects the activation of the 
alpha-motorneurons by the Ia afferent pathways (Schieppati 1987). Previous literature 
has shown mixed effects for caffeine on H-reflex amplitude, with several investigations 
finding increased spinal excitability (Eke-Okoro 1982; Walton et al. 2003) and numerous 
reporting equivocal results (Behrens et al. 2015a; Behrens et al. 2015b; Kalmar and 
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Cafarelli 1999). Our results are in line with the later, in which we found no significant 
change in Soleus H-Reflex (when normalized to M-Wave) at any time point. It is 
important to note that no significant change in SOL M-Wave were found from pre- to 
post-testing in any condition, which indicates that the probe placement was not different 
during the SOL M-Wave measurement and a valid M-Wave measurement was achieved 
(Walton et al. 2003). In line with these findings, no significant change in RF M-Wave, 
VL M-Wave or Normalized EMG AMP were found from pre- to post-testing in either 
condition, which is consistent with the findings of (Kalmar and Cafarelli 2006). Thus, our 
data does not support the previous reports of increased neural drive or corticospinal 
excitability following caffeine supplementation.  
The lack of change in spinal and supraspinal properties in the present investigation 
points towards peripheral mechanisms as the logical explanation for the maintained MVT 
following caffeine supplementation. Indeed, several previous investigations have reported 
enhanced skeletal muscle twitch properties following caffeine supplementation 
(Bazzucchi et al. 2011; Kalmar and Cafarelli 2006). However, it is crucial to 
acknowledge the decrease in nearly all evoked twitch properties 1-hour post ingestion of 
PLA. Indeed, the work of Bazzucchi et al. (2011), who utilized a very similar 
experimental design, also reported decreased twitch properties in the post-placebo 
condition. Additionally, while values for twitch properties were not reported, Kalmar and 
Cafarelli (1999) reported a decrease in MVC strength in the placebo condition, which 
may have been attributed to declining twitch properties. Although neither of these authors 
speculated on potential mechanisms for this decreased contractile function, we speculate 
this may be due to a decrease in muscle temperature following the 1-hour rest period, as 
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muscle decreased muscle temperature has been shown to alter muscle contractile 
properties (Davies and Young 1983; Holewijn and Heus 1992). Indeed, this hypothesis 
has been proposed previously by Fowles and coworkers (2000), who reported significant 
decreases in twitch torque following not only maximal passive stretching of the plantar 
flexors, but in the control condition as well. The authors speculated that the decrease in 
evoked twitch torque in the control condition was most likely due to a reduced muscle 
temperature (Fowles et al. 2000). However, muscle temperature was not recorded during 
the present investigation, and therefore, this hypothesis remains speculative. It is also 
important to acknowledge that caffeine supplementation maintained MVIC and 
contractile properties near baseline values, which is consistent with previous work in the 
quadriceps musculature by Behrens et al. (2015a). Thus, our data suggest that while 
caffeine did not significantly improve skeletal muscle function, caffeine clearly exhibited 
an ergogenic effect to offset the decline seen in the placebo condition. This has 
significant physiological implications, as alterations in calcium handling have been the 
most commonly proposed peripheral mechanism of caffeine and has been supported by 
numerous in vitro investigations. For example, in vitro evidence has suggested that there 
is an increase intracellular calcium from the sarcoplasmic reticulum and/or increased 
sensitivity of the muscle fibers with caffeine intake (Allen et al. 2008), potentially due to 
the interaction of caffeine with the ryanodine receptors of the sarcoplasmic reticulum 
(Penner et al. 1989).  While we did not measure intracellular in the present investigation, 
our data provide non-invasive evidence of potential alterations in calcium handling at the 
contractile level, as evidenced by lack of decline in contractile function following CAF 
seen in the PLA condition. This is in contrast to a recent investigation, where authors not 
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only reported a lack of improvement in skeletal muscle twitch properties, but also 
proposed that toxic dosages of caffeine are needed to increase skeletal muscle function 
based on an animal model used in the same investigation (Neyroud et al. 2018). 
However, in the present investigation a particularly interesting change is seen in -dt/dtD, 
where our data suggests a -7.4% slower -dt/dtD at PLAPOST, when compared to PLAPRE, 
and a 0.4% increase in -dt/dtD was found from CAFPRE to CAFPOST. Further support for 
altered twitch behavior can be found in Figure 9, where significant relationships we 
found between the percent change in contractile function and the percent change in 
MVIC. However, it is clear that these relationships are negatively shifted on both the x 
and y axes in the PLA condition. Thus, it seems logical that alterations in Ca2+ handling 
at the cellular level are most likely responsible for the lack of decline in MVT seen in the 
CAF condition. Interestingly, Meyers and Cafarelli (2005) reported a similar hypothesis 
when they reported that caffeine offset the decline in contractile function during fatigue, 
thus increasing time to fatigue. The authors reported the evoked twitch amplitude and the 
maximal relaxation rate were significantly correlated in both caffeine and placebo 
conditions, suggesting that the increase in time of fatigue may be partially explained by 
caffeine’s effects on calcium reuptake and twitch force(Meyers and Cafarelli 2005). 
Finally, another potential mechanism of caffeine proposed by previous authors is 
increased conduction velocity Bazzucchi et al. (2011), which could potentially be a 
byproduct of increased calcium sensitivity at the muscle level. Future research is needed 






Fatigue, in terms of exercise, is defined as a reduction of maximal muscle force or 
power (Taylor et al. 2000). As skeletal muscle force is modulated through the interplay of 
MU recruitment and rate coding (i.e. firing rate), it is well established during a fatiguing 
exercise bout, larger, higher-threshold MUs are progressively recruited as the smaller, 
lower-threshold MUs fatigue (Contessa et al. 2016; Muddle et al. 2018). This process, 
known as the size the principle (Henneman 1957), sets the foundation for the 
maintenance of force production throughout fatiguing contractions. While there are both 
non-invasive and invasive measures of MU behavior, the surface EMG signal represents 
a global activation of the muscle (Farina et al. 2004; Jenkins et al. 2016). In submaximal 
fatiguing efforts, such as the protocol used in the present investigation, a progressive 
increase in the EMG amplitude and integrated EMG are hallmarks of the fatigue process 
(Cifrek et al. 2009; Jenkins et al. 2015a; Naeije and Zorn 1982). Indeed, the present data 
display significant increases in normalized RFAMP and VLAMP, as well as RFiEMG and 
VLiEMG over the course of the fatigue protocol, independent of condition. Our results 
appear to be consistent with the size principle, as evidenced by the significant, positive 
relationship between in the MUAP vs. RT relationship. Our data also indicate an increase 
in the A term, along with the subsequent decrease in b term, of the MUAP vs. RT 
relationship across the fatigue protocol, indicating the progressive recruitment of larger 
MUs over time. Additionally, no significant differences were seen between conditions, 
indicating that caffeine does not appear to alter this process, or increase the recruitment 
of high-threshold MUs, as previous hypothesized (Bazzucchi et al. 2011). As the A term 
represents the theoretical MUAP of the smallest recruited MU, and the b term represents 
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the MUAP growth per unit of increase in RT (Miller et al. 2019), our data suggest 
progressively larger MUs and a slower growth rate were required to maintain the required 
force production through the fatigue protocol (Figure 4). While only a few exceptions to 
the size principle have been noted in the literature (Bawa and Murnaghan 2009; Bawa et 
al. 2006; Westgaard and De Luca 1999), there is conflicting literature on alterations in 
firing rate behavior during fatigue. For example, previous investigations have reported 
both increases (Contessa et al. 2009; Contessa et al. 2016; Muddle et al. 2018) and 
decreases (McManus et al. 2015; Mottram et al. 2005) in the firing rates of active MUs 
with fatigue. The lack of change in the slope or y-intercept of the MFR vs. RT 
relationship, along with the previously reported increased MUAP amplitude, suggest that 
both MU firing rates and recruitment modulation were utilized to maintain force 
production. Thus, our data provide support for the hypothesis of several previous 
investigators, who suggested an increase in excitation to the MU pool, and thus, higher 
MU firing rates, to counteract the decreasing twitch forces seen with the development of 
fatigue (Contessa et al. 2016; De Luca and Contessa 2015).  
  To further support this hypothesis, our data show significant decreases in twitch 
properties from pre- to post-fatigue, regardless of condition. For example, along with the 
significant reductions seen across time, we saw an approximate 56.9%, 52.4%, and 
59.2% reduction in pTTD, +dT/dTD, and –dT/dTD, respectively, when collapsed across 
conditions. As the doublet stimulations reflect the contractile ability of the muscle by 
removing the series elastic component (Herda et al. 2013), the present data represent 
clear declines in contractile function with fatigue (Dolmage and Cafarelli 1991). 
Consistent with previous fatigue literature, our data indicated a significant decrease in 
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VLMDF and RFMDF over the course of the fatiguing exercise protocol. Previous research 
has suggested that EMG median power frequency (MDF) is altered by fatigue, most 
likely through metabolite accumulation, in which conduction velocity is slowed (Beck et 
al. 2005; Bouissou et al. 1989; Brody et al. 1991; Hill et al. 2016). Thus, the significant 
decrease in EMG MDF seen in the present study supports the decline in skeletal muscle 
function following the fatiguing protocol. In concert with the decline in twitch properties, 
we reported a significant decrease in %VA following the fatigue protocol, independent of 
condition. This may lend support to central activation failure (Kent-Braun 1999) and/or 
locomotor fatigue (Amann and Dempsey 2008), as it appears both central and peripheral 
factors were present.   
Previously literature has suggested that caffeine may increase time to exhaustion 
during submaximal exercise (Kalmar and Cafarelli 1999; Meyers and Cafarelli 2005; 
Pethick et al. 2018; Plaskett and Cafarelli 2001). However, the data in the present 
investigation does not support this, as evidenced by the lack of significant change in 
TQIMP between conditions. Despite TQAVG being significantly higher in the CAF 
condition, this did not manifest into increased time to fatigue or work performed, as 
measured through TQIMP. Thus, our findings are in agreement with Fimland et al. (2010), 
who found no ergogenic benefit during and recovery from a submaximal fatiguing 
exercise protocol. It is interesting to note that Pethick et al. (2018) reported a significantly 
slower loss of torque complexity in the caffeine condition, leading to an approximately 
30% increase in time to fatigue. As TQCV can be considered a crude measure of 
complexity, it is interesting to note that TQCV was significantly lower in the CAF 
condition in the present investigation (Figure 10). However, this did not amount to an 
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increase in time to fatigue or total work performed, potentially due to decrements 
associated with central and/or peripheral fatigue mechanisms previously discussed.  
5.3 CYP1A2 Genotype  
The role of genetics in exercise and nutrition has recently become an area of 
interest for a number of investigations, with the lofty goal of providing a genetic link to 
the variable responses seen in human subjects research. Specific to caffeine, the CYP1A2 
genotype has become the topic of numerous recent investigations. Interestingly, to date, 
the results of these investigations have been mixed, with some authors reporting genotype 
specific performance benefits ((Guest et al. 2018; Salinero et al. 2017; Womack et al. 
2012), with others showing equivocal results (Algrain et al. 2016; Giersch et al. 2018; 
Puente et al. 2018). The results of the present investigation align with the later, as we 
reported no significant performance or neuromuscular differences between CYP1A2 
genotypes. While %VA was significantly different between genotypes, this is most likely 
due to the more homogenous training background of the SLOW group, compared to the 
higher variability in the FAST group. Further, as differences in %VA were not 
attributable to caffeine consumption, there is no logical pathway by which the CYP1A2 
genotype would alter %VA independent of caffeine consumption. Thus, the results of our 
investigation suggest that CYP1A2 genotype does not mediate neuromuscular function 
and fatigability of the quadriceps following caffeine consumption in college-aged males.  
5.4 Conclusions 
In contrast to much of the previous literature, the present investigation provides 
data that 6 mg/kg/bw of caffeine anhydrous provides limited ergogenic benefits to 
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exercise performance. However, our data suggests that caffeine alters peripheral skeletal 
muscle properties, as opposed to mediating muscle activation through spinal or 
supraspinal mechanisms as previously suggested. Based on these data, it can be 
hypothesized that caffeine may act through alterations in calcium handling and/or 
changes in calcium sensitivity at the muscle fiber level, as proposed by previous 
investigators. Additionally, the present data does not support the notion that the CYP1A2 
genotype mediates the acute responses to caffeine in college-aged males. However, more 
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